IJCRT.ORG

ISSN: 2320-2882

d189



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

ANTHRACENE DERIVATIVES AS ANANTI BREAST CANCER


Mr. Vijay Vinayak Pawar Tal. Malegaon Dist. Nashik (423203) Co- Author: Dr. Nilam Jain Associate Professor Oriental University Indore

Abstract:

New potential chemotherapeutic strategies are required to overcome multidrug resistance (MDR) in cancer. In this study, Antibacterial activities of the synthesized compounds were evaluated against gram (+) Staphylococcus aureus and gram (-) Klebsilla aerogenes by measuring zone of inhibition. The antifungal activities of the synthesized compounds were evaluated against Candida albicans by disc diffusion method. Compounds screened for antibacterial activity against Bacillus subtilis, Escherichia coli. and antifungal activity against Candida albicans, Aspergillus Niger by cup plate method.

All the compounds of the series were screened for their antibacterial and antifungal activity studies. Substitution of hydroxyl and halo groups emerged as active in both antibacterial and antifungal screening. The reported antibacterial activity of 3-benzoyl-2-oxo/thioxo-1, 2, 3, 4- tetrahydropyrimidine analogues. 5-Acyl-6-methyl-4-substituted-2-oxo/thioxo-1,2,3,4- tetrahydropyrimidines were synthesized by cyclocondensation reaction between appropriate aldehyde, acetoacetate and urea/thiourea in presence of aluminium chloride and hydrochloric acid which upon treatment with benzoyl chloride in presence of aluminium chloride in presence of pyridine in benzene furnish the title compounds. The compounds have been tested for antibacterial activity against *staphylococcus aureus*.

PLAN OF WORK:



02. INTRODUCTION

2.1 Selection of disease:

2.1.1 Infectious diseases:

Infection is invasion or colonization of the body by pathogenic microorganisms. Human beings have defense mechanism to keep healthy. Unbroken skin and mucous membranes are effective barriers against microbial invasion. Within the body, certain cells and certain specialized proteins called antibodies can work to together to destroy microbes. In spite of defense humans are still susceptible to pathogens. Persons who are weak, sick and have cancer or are diabetic have increased susceptibility to infections.

Infectious disease is primary cause of death worldwide. Infectious disease mortality decreased markedly during most of the 20th century. However between 1980 and 1992 the death rate from infectious disease increased 58%. The sharp increase in infectious disease deaths in 1918 and 1919 was caused by influenza pandemic, which killed more than 20 million people worldwide. This episode illustrates the volatility of infectious disease death rates.

Infections are classified according to the extent to which host body is affected. Local infection is one in which invading microorganisms are limited to relatively small area of the body. Systemic infection is one in which microorganisms are spread throughout the body by the blood or lymph. Agents of the local infection enter a blood or lymphatic vessel and spread to other specified areas of the body called focal infection. The presence of bacteria in blood is known as bacteremia and if the bacteria actually multiply in blood the condition is called sepsis. Toxemia is the presence of toxins in blood. Viremia refers as presence of viruses in blood. Primary infection is acute infection that causes initial illness. Secondary infection caused by opportunistic pathogen after the primary infection has weakened the body's defense.

2.1.1.1 Diseases:

Disease occurs when an infection results in any change from a state of health. Disease is an abnormal state in which part or all of the body is not properly adjusted or incapable of performing its normal functions. Majority of bacteria are harmless or beneficial, quite a

few bacteria are pathogenic. Pathogenic bacteria are bacteria that cause bacterial infection and are major cause of human death. One of the bacterial diseases with highest disease burden is tuberculosis, caused by the bacterium Mycobacterium tuberculosis, which kills about 2 million people a year, mostly in sub-Saharan Africa. Pathogenic bacteria contribute to diseases, such as pneumonia, tetanus, typhoid fever, diphtheria, syphilis, leprosy, tuberculosis, cholera and food borne illness. Microorganisms can cause tissue damage by releasing a variety of toxins or destructive enzymes. Clostridium tetanus releases toxins which produce shock and sepsis. Each species of pathogen has a characteristic spectrum of interactions with its human hosts. Some organisms, such as Staphylococcus or Streptococcus, can cause skin infections, pneumonia, meningitis and even overwhelming sepsis, a systemic inflammatory response producing shock, massive vasodilation and death. Yet these organisms are also part of the normal human flora and usually exist on the skin or in the nose without causing any disease at all. Other organisms invariably cause disease in humans, such as the rickettsia, which are obligate intracellular parasites able to grow and reproduce only within the cells of other organisms. One species of rickettsia causes typhus, while another causes rocky mountain spotted fever. Chlamydia, another phylum of obligate intracellular parasites, contains species that can cause pneumonia, or urinary tract infection and may be involved in coronary heart disease. Pseudomonas aeruginosa, Burkholderia cenocepacia, and Mycobacterium avium are opportunistic pathogens and cause disease mainly in people suffering from immunosuppression or cystic fibrosis. Microbial diseases can be prevented by immunizations and controlled by drugs^{1,2}. 1JCR

2.1.1. 2 Development of Disease:

Development of disease follows certain sequence.

Incubation period: It is time interval between initial infection and first appearance of any signs or symptoms. Time of incubation period depends on specific microorganism involved, its virulence and number of microorganisms and resistance of the host.

Prodromal period: This period is relatively short period that follows the period of incubation in some diseases and characterized by early, mild symptoms of diseases.

Period of illness: During period of illness disease is most acute. Person exhibits over signs and symptoms of disease, such as fever, chills, muscle pain, sore throat and GIT disturbances. During the period of illness, number of white blood cells may increase or decrease. Generally patient immune response and other defense mechanisms overcome the pathogen and period of illness ends.

Period of convalescence: Person regains strength and the body returns to its prediseased state. Recovery has occurred.

2.1.1. 3 Anti-microbial Agents:

An antimicrobial drug is a chemical substance that destroys pathogenic microorganisms with minimal damage to host tissues. Antibiotics have revolutionized the medical care in the 20th century. With the discovery of antibiotics people were convinced that infectious diseases might someday be wiped out. Diseases that were once life threatening, such as pneumonia, had become curable. The success of antibiotics in therapy related fields has made them one of the most important products of the drug industry today. However, the emergence of superbugs *i.e.* bacteria that resist the effects of the most powerful antibiotics are posing a great challenge to the field of medicines. Thus scientists are working to find new ways to defeat bacteria that are increasingly resistant to the antibiotics already available.

2.1.1. 4 Mechanisms of anti-microbial action:

A. Inhibition of cell metabolism

Antibacterial agents which inhibit cell metabolism are called antimetabolites. These compounds inhibit the metabolism of a microorganism, but not the metabolism of the host. They do this by inhibiting an enzymecatalysed reaction which is present in the bacterial cell, but not in animal cells *e.g.* sulfonamides.

B. Inhibition of bacterial cell wall synthesis

Inhibition of cell wall synthesis leads to bacterial cell lysis (bursting) and death e.g. penicillin.

C. Interactions with the plasma membrane

Some antibacterial agents interact with the plasma membrane of bacterial cells to affect membrane permeability. This has fatal results for the cell e.g. tyrothricin.

D. Disruption of protein synthesis

Disruption of protein synthesis means that essential enzymes required for the cells survival can no longer be made e.g. chloramphenicol.

E. Inhibition of nucleic acid transcription and replication

Inhibition of nucleic acid function prevents cell division and the synthesis of essential enzymes *e.g.* nalidixic acid.

2.1.1. 5 Drug resistance:

Antibiotic resistance occurs when bacteria change in some way that reduces or eliminates the effectiveness of drug, chemicals, or other agents designed to cure or prevent the infection. The bacterial cell may change the structure of its cell membrane and prevent the drug from entering the cell. Alternatively, an enzyme may be produced which destroys the drug. If the drug is targeting a specific enzyme, then the bacterium may synthesize an excess of the enzyme. Thus the bacteria survive and continue to multiply causing more harm. Widespread use of antibiotics promotes the spread of antibiotic resistance. Definition of resistance is based on bacterial susceptibility to antibacterial agent. This is typically achieved by determining the minimal inhibitory concentration that inhibits the growth of bacteria. Thus resistance is defined as "bacteria that are not inhibited by the systemic concentration of the agent with normal dosage schedule and fall in the minimal inhibitory concentration ranges". Likewise the multiple drug resistance is defined as the resistance to two or more drugs or drug classes.

2.1.1. 6 Mechanism of antibiotic resistance:

Bacteria may display antibiotic resistance by one or more of the following mechanisms:

- A. They may lack a target for the antibiotic. For example Chlamydia does not have peptidoglycan and are not affected by the action of penicillin.
- B. The antibiotic target may be inaccessible. For example peptidoglycan in Gram- negative bacteria is not easily entered to penicillins that cannot penetrate the Gram-negative outer membrane of the cell and efflux pumps can actively pump out antibiotics from cells. For example resistance to tetracyclines by Gram negative bacterial strain occurs in this way.
- C. The antibiotic target may be modified to prevent the action of the drug. For example trimethoprim resistance is affected by alterations in to the DHFR target

enzyme. Quinolone resistance is manifest by mutations in the DNA gyrase, which prevent the formation of drug-ligand complex.

D. The antibiotic may be chemically modified. For example chloramphenical resistance is mostly affected by acetylation by using chloramphenical acetyltransferase enzyme³.

2.1.2 Cancer:

Approximately 29% of world's unhealthy population is suffering from cancer. It shoes its major role in deaths worldwide. An estimated 12.66 million people were diagnosed with cancer across the world in 2008. This equates to around 188 cases for every 100,000 people (using the crude rate). The number of new cases ranged from 67,000 in middle Africa to 3.72 million in eastern Asia. As expected from the size of Asia's population, the majority of cases (48%) occurred there. Just four cancer sites – lung, female breast, colorectal and stomach accounted for two-fifths (41%) of the world's total⁴.

Cancer is a disease in which there is uncontrolled multiplication and spread within the body of the body's own cells. It is a potentially fatal disease caused mainly by environmental factors that mutate genes encoding critical cell-regulatory proteins. There are over 200 different known cancers that afflict humans. The cancer-causing agents (carcinogens) can be present in food and water, in the air, and in chemicals and sunlight that people are exposed to. Since epithelial cells cover the skin, line the respiratory and alimentary tracts, and metabolize ingested carcinogens, it is not surprising that over 90% of cancers occurs inepithelia⁵.

In terms of behavior, tumours are either 'benign' or 'malignant'. Benign tumours are generally slow-growing expansive masses that compress rather than invade surrounding tissue. As such they generally pose little threat, except when growing in a confined space like the skull, and can usually be readily excised. However, many so- called benign tumours have malignant potential, notably those occurring in the large intestine, and these should be removed before malignancy develops. Malignant tumours are usually rapidly growing, invading surrounding tissue and, most significantly,

colonizing distant organs. The ability of tumour cells to detach from the original mass (the primary tumour) and set up a metastasis (secondary tumour) discontinuous with the primary is unequivocal proof of malignancy. Tumours are also classified according to their tissue of origin; recognition of the parent tissue in a lymph node metastasis could establish the location of a hitherto undiagnosed primary tumour. Much of cell behaviour (division and differentiation) is governed by the effects of polypeptide growth factors which, because of their water-soluble nature, cannot diffuse through the plasma membrane of the cell, instead interacting with membrane-bound glycoprotein receptors that transduce the first message (the growth factor or ligand) into a series of intracellular signals that promote or inhibit the transcription of specific genes⁶.

2.1.2.1 Cancer pathophysiology:

Cancer is fundamentally a disease of failure of regulation of tissue growth. In order for a normal cell to transform into a cancer cell, the genes which regulate cell growth and differentiation must be altered. The affected genes are divided into two broad categories. Oncogenes are genes which promote cell growth and reproduction. Tumor suppressor genes are genes which inhibit cell division and survival. Malignant transformation can occur through the formation of novel oncogenes, the inappropriate over-expression of normal oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, changes in many genes are required to transform a normal cell into a cancer cell⁷.

Genetic changes can occur at different levels and by different mechanisms. The gain or loss of an entire chromosome can occur through errors in mitosis. More common are mutations, which are changes in the nucleotide sequence of genomic DNA. Large- scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs when a cell gains many copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. Translocation occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the Philadelphia chromosome, or translocation of chromosomes 9 and 22, which occurs in

chronic myelogenous leukemia, and results in production of the BCR-ablfusion protein, an oncogenic tyrosine kinase. Small-scale mutations include point mutations, deletions, and insertions, which may occur in the promoter region of a gene and affect its expression, or may occur in the gene's coding sequence and alter the function or stability of its protein product. Disruption of a single gene may also result from integration of genomic material from a DNA virus or retrovirus, and resulting in the expression of *viral* oncogenes in the affected cell and its descendants. Replication of the enormous amount of data contained within the DNA of living cells will probabilistically result in some errors (mutations). Complex error correction and prevention is built into the process, and safeguards the cell against cancer. If significant error occurs, the damaged cell can "self- destruct" through programmed cell death, termed apoptosis. If the error control processes fail, then the mutations will survive and be passed along to daughter cells. Some environments make errors more likely to arise and propagate. Such environments can include the presence of disruptive substances called carcinogens, repeated physical injury, heat, ionising radiation, or hypoxia⁸.

2.1.2.2 Selection of Specific Cance<mark>r Typ</mark>e: Brea<mark>st Can</mark>cer:

Female breast cancer incidence rates vary nearly five-fold across the regions of the world. In 2008, rates ranged from around 20 per 100,000 in Eastern and Middle Africa to 90 per 100,000 in Western Europe. The countries with the highest incidence rates in 2008 were Belgium and Denmark (109 and 101 per 100,000, respectively). The incidence rate for UK women was high at 11th highest out of 184 countries worldwide.

Breast cancer is the most common cause of death from cancer in women worldwide, estimated to be responsible for almost 460,000 deaths in 2008. There is less variation in female breast cancer mortality across the regions of the world, largely due to better survival in the (high incidence) developed countries, with rates ranging from 6 per 100,000 in Eastern Asia to 19 per 100,000 in Southern and Western Africa in 2008⁹.

By studying types and statistics of various cancers, it is concluded that Breast Cancer is era where lot more work is needed as it ranks second in all cancer types and first in cancers associated with women worldwide. That's why we have particularly selected breast cancer as our target of research.

Breast Cancer

Breast cancer is a malignant tumor that starts in the cells of the breast. A malignant tumor is a group of cancer cells that can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. The disease occurs almost entirely in women, but men can get it too.

The first noticeable symptom of breast cancer is typically a lump that feels different from the rest of the breast tissue. More than 80% of breast cancer cases are discovered when the woman feels a lump. The earliest breast cancers are detected by a mammogram. Lumps found in lymph nodes located in the armpits can also indicate breast cancer. Indications of breast cancer other than a lump may include thickening different from the other breast tissue, one breast becoming larger or lower, a nipple changing position or shape or becoming inverted, skin puckering or dimpling, a rash on or around a nipple, discharge from nipple/s, constant pain in part of the breast or armpit, and swelling beneath the armpit or around the collarbone. Pain ("mastodynia") is an unreliable tool in determining the presence or absence of breast cancer, but may be indicative of other breast health issues. Inflammatory breast cancer is a particular type of breast cancer which can pose a substantial diagnostic challenge. Symptoms may resemble a breast inflammation and may include itching, pain, swelling, nipple inversion, warmth and redness throughout the breast, as well as an orange-peel texture to the skin referred to as peau d'orange; the absence of a discernible lump delays detection dangerously. Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome presents as eczematoid skin changes such as redness and mild flaking of the nipple skin. As Paget's advances, symptoms may include tingling, itching, increased sensitivity, burning, and pain. There may also be discharge from the nipple. Approximately half of women diagnosed with Paget's also have a lump in the breast. In rare cases, what initially appears as a fibroadenoma (hard movable lump) could in fact be a phyllodes tumor. Phyllodes tumors are formed within the stroma (connective tissue) of

the breast and contain glandular as well as stromal tissue. Phyllodes tumors are not staged in the usual sense; they are classified on the basis of their appearance under the microscope as benign, borderline, or malignant.

Occasionally, breast cancer presents as metastatic disease, that is, cancer that has spread beyond the original organ. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. Common sites of metastasis include bone, liver, lung and brain. Unexplained weight loss can occasionally herald an occult breast cancer, as can symptoms of fevers or chills. Bone or joint pains can sometimes be manifestations of metastatic breast cancer, as can jaundice or neurological symptoms. These symptoms are called *non-specific*, meaning they could be manifestations of many other illnesses. Most symptoms of breast disorders, including most lumps, do not turn out to represent underlying breast cancer. Less than 20% of lumps for example are cancer and benign breast diseases such as mastitis and fibroadenoma of the breast are more common causes of breast disorder symptoms. Nevertheless, the appearance of a new symptom should be taken seriously by both patients and their doctors, because of the possibility of an underlying breast cancer at almost any age¹⁰.

2.1.2.3 Breast Cancer Statistics:

Breast cancer is by far the most common cancer diagnosed in women worldwide (ranking second in both sexes combined). An estimated 1.38 million women across the world were diagnosed with breast cancer in 2008 (Fig. 2.2) accounting for nearly a quarter (23%) of all cancers diagnosed in women (11% of the total in men and women). Incidence is generally high in the developed countries and markedly lower in developing countries, though differences in population sizes mean that approximately equal numbers of cases were diagnosed in the developed and developing regions in 2008 (around 690,000 cases each). Breast cancer incidence has increased in most countries worldwide in the last decades, with the most rapid increases occurring in many of the developing countries. Reproductive behavior and the use of exogenous hormones, as well as differences in weight, exercise, diet and alcohol consumption, are thought to underlie the differences.

It has been estimated that breast cancer rates in developed countries could be half that of current rates if women had more children and breastfed for longer⁴.




Fig 2.1 Cancer Type Incidence Statistics

2.1.2.4 Breast cancer pathophysiology:

Normal cells divide as many times as needed and stop. They attach to other cells and stay in place in tissues. Cells become cancerous when they lose their ability to stop dividing, to attach to other cells, to stay where they belong, and to die at the proper time. Normal cells will commit cell suicide (apoptosis) when they are no longer needed. Until then, they are protected from cell suicide by several protein clusters and pathways. One of the protective pathways is the PI3K/AKT pathway; another is the RAS/MEK/ERK pathway. Sometimes the genes along these protective pathways are mutated in a way that turns them permanently "on", rendering the cell incapable of committing suicide when it is no longer needed. This is one of the steps that causes cancer in combination with other mutations. Normally, the PTEN protein turns off the PI3K/AKT pathway when the cell is ready for cell suicide. In some breast cancers, the gene for the PTEN protein is mutated, so the PI3K/AKT pathway is stuck in the "on" position, and the cancer cell does not commit suicide. Mutations that can lead to breast cancer have been experimentally linked to estrogen exposure. Failure of immune surveillance, the removal of malignant cells

throughout one's life by the immune system. Abnormal growth factor signaling in the interaction between stromal cells and epithelial cells can facilitate malignant cell growth. In breast adipose tissue, over expression of leptin leads to increased cell proliferation and cancer.

In the United States, 10 to 20 percent of patients with breast cancer and patients with ovarian cancer have a first- or second-degree relative with one of these diseases. The familial tendency to develop these cancers is called hereditary breast—ovarian cancer syndrome. The best known of these, the BRCA mutations, confer a lifetime risk of breast cancer of between 60 and 85 percent and a lifetime risk of ovarian cancer of between 15 and 40 percent. Some mutations associated with cancer, such as p53, BRCA1 and BRCA2, occur in mechanisms to correct errors in DNA. These mutations are either inherited or acquired after birth. Presumably, they allow further mutations, which allow uncontrolled division, lack of attachment, and metastasis to distant organs. However there is strong evidence of residual risk variation that goes well beyond hereditary BRCA gene mutations between carrier families. This is caused by un observed risk factors. This implicates environmental and other causes as triggers for breast cancers. The inherited mutation in BRCA1 or BRCA2 genes can interfere with repair of DNA cross links and DNA double strand breaks (known functions of the encoded protein) These carcinogens cause DNA damage such as DNA cross links and double strand breaks that often require repairs by pathways containing BRCA1 and BRCA2. However, mutations in BRCA genes account for only 2 to 3 percent of all breast cancers. About half of hereditary breast—ovarian cancer syndromes ICR involve unknown genes¹⁰.

2.1.3 Selection of target: Didydrofolate reductase enzyme:

Dihydrofolate reductase, or DHFR, is an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, using NADPH as electron donor, which can be converted to the kinds of tetrahydrofolate cofactors used in 1-carbon transfer chemistry. In humans, the DHFR enzyme is encoded by the DHFR gene. 11, 12 It is found in the g11→g22 region of chromosome 5.13 Bacterial species possesses distinct DHFR enzymes (based on their

pattern of binding diaminoheterocyclic molecules), but mammalian DHFRs are highly similar. 14

DHFR has a critical role in regulating the amount of tetrahydrofolate in the cell. Tetrahydrofolate and its derivatives are essential for purine and thymidylate synthesis, which are important for cell proliferation and cell growth. DHFR plays a central role in the synthesis of nucleic acid precursors, and it has been shown that mutant cells that completely lack DHFR require glycine, an amino acid, and thymidine to grow. DHFR has also been demonstrated as an enzyme involved in the salvage of tetrahydrobiopterin from dihydrobiopterin.

DHFR can be targeted in the treatment of cancer. DHFR is responsible for the levels of tetrahydrofolate in a cell, and the inhibition of DHFR can limit the growth and proliferation of cells that are characteristic of cancer. Methotrexate, a competitive inhibitor of DHFR, is one such anticancer drug that inhibits DHFR. Other drugs include trimethoprim and pyrimethamine. These three are widely used as antitumor and antimicrobial agents. Whether or not these are potent anticancer agents is unclear.

Trimethoprim has shown to have activity against a variety of Gram-positive bacterial pathogens. However, resistance to trimethoprim and other drugs aimed at DHFR can arise due to a variety of mechanisms, limiting the success of their therapeutical uses. Resistance can arise from DHFR gene amplification, mutations in DHFR, decrease in the uptake of the drugs, among others. Regardless, trimethoprim and sulfamethoxazole in combination has been used as an antibacterial agent for decades.²⁰

Folic acid is necessary for growth,²¹ and the pathway of the metabolism of folic acid is a target in developing treatments for cancer and microbial infections. DHFR is one such target. A regimen of fluorouracil, doxorubicin, and methotrexate was shown to prolong survival in patients with advanced gastric cancer. Further studies into inhibitors of DHFR can lead to more ways to treat cancer and microbial infections.

03. Research envisaged

03.1 Need of work:

With a wide range of antibacterial agents available in medicine, it may seem surprising that medicinal chemists are still actively seeking new and improved antibacterial agents. The reason is mainly due to emerging infectious diseases and the increasing number of multi-drug resistant microbial pathogens which make the treatment of infectious diseases an important and pressing global problem. Drugs, which are active today, may become inactive after several years. Though some of the drugs are highly effective, they are associated with toxic side effects. Thats why bacterial infection is one of chalange due to drug resistance and toxicity¹.

Approximately 29% of world's unhealthy population is suffering from cancer. It shoes its major role in deaths worldwide. An estimated 12.66 million people were diagnosed with cancer across the world in 2008. This equates to around 188 cases for every 100,000 people (using the crude rate). The number of new cases ranged from 67,000 in middle Africa to 3.72 million in eastern Asia. As expected from the size of Asia's population, the majority of cases (48%) occurred there. Just four cancer sites – lung, female breast, colorectal and stomach accounted for two-fifths (41%) of the world's total².

Therefore, a substantial research for the discovery and synthesis of new more and more potent, safer drugs than the existing ones classes of antimicrobial and anti-cancer agents is needed.

03.2 Aim and Objective:

The literature reveals that derivatives of anthracene possess versatile biological activities such as antibacterial, antifungal, antiinflammatory, anticancer, antiviral, antioxidant, calcium channel blocker and antihypertensive. anthracene derivatives are also reported to have powerful activities such as antituberculosis, anticancer, antiarrhythmic, antibacterial, antifungal and anticonvulsant activities. fluroquinolone derivatives are also reported to have powerful antimicrobial activity. It has been observed that the incorporation of more than one bioactive heterocyclic moiety into a single framework

may result into the production of novel heterocycles with enhanced bioactivity and biological properties such as potency, selectivity, toxicity and metabolic stability. It is well known that anthracene and fused heterocyclic anthracene derivatives are of great biological interest, especially as antiviral, antitumor and antimicrobial agents. This prompts us to synthesize a series of novel fused anthracene derivatives and evaluate their antimicrobial activity³⁻⁷.

The chemistry and the synthesis of anthracene 9,11 dione have been attracting widespread attention in recent years. The present popularity of these anthracene 9,11 dione is mainly due to their close structural relationship to the clinically important 8,10 diaza benzo anthracene 9,11 dione anti-microbial and anti-cancer agents. Anthracene 9,11 dione is known as a versatile heterocyclic compound which has been subjected to a large variety of structural modifications in order to synthesize derivatives with different biological properties. Their various condensed derivatives are reported to possess calcium antagonist, anti-inflammatory, analgesic, antitumor, antidepressant, antibacterial, and antifungal effects. The anthracene 9,11 dione can be synthesized by biginelli reaction by condensation of aromatic aldehyde, beta napthol and dimedone. Multi-component reactions (MCRs) are useful organic reactions involving three or more starting materials which react to give a product. They constitute a major part in the present day organic synthesis with advantages ranging from lower reaction times, increased reaction rates to higher yields and reproducibility⁸⁻⁹.

The versatile utility of anthracene has pharmacological interest, prompts us to prepare series of anthracene derivative.

In the present work we aim:

- To perform molecular modeling by using Vlife MDS 4.3 software
- 2. To establish the scheme for synthesis of selected compounds from molecular modeling.
- 3. To achieve the synthesis of series of anthracene 9,11 dione.
- 4. To characterize the synthesized compound by physical data melting point, thin layer chromatography and spectral analysis like infrared spectroscopy, nuclear magnetic resonance spectroscopy and mass spectroscopy.

- 5. To perform biological screening of the synthesized compounds for % topoisomerase II enzyme inhibition assay, antimicrobial activity and in-vitro anti- cancer activity.
- 6. To carry out 2D QSAR and 3D QSAR for study of the compounds for % topoisomerase II enzyme inhibition assay and anti-microbial activity.

03.1 Topoisomerase enzyme receptor structure

Topoisomerases are enzymes that regulate the overwinding or underwinding of <u>DNA</u>. The winding problem of DNA arises due to the intertwined nature of its double-helical structure. During <u>DNA replication</u> and <u>transcription</u>, DNA becomes overwound ahead of a replication fork. If left unabated, this torsion would eventually stop the ability of RNA & DNA polymerase involved in these processes to continue down the DNA strand.

In order to prevent and correct these types of topological problems caused by the double helix, topoisomerases bind to either single-stranded or double-stranded DNA and cut the phosphate backbone of the DNA. This intermediate break allows the DNA to be untangled or unwound, and, at the end of these processes, the DNA backbone is resealed again. Since the overall chemical composition and connectivity of the DNA do not change, the tangled and untangled DNAs are chemical isomers, differing only in their global topology, thus their name. Topoisomerases are isomerase enzymes that act on the topology of DNA.

Bacterial topoisomerase and human topoisomerase proceed via the same mechanism for replication and transcription.

Discovery

James C. Wang was the first to discover a topoisomerase when he identified *E. coli* topoisomerase I. Topo EC-codes are as follows: type I, EC 5.99.1.2; type II: EC 5.99.1.3. His discovery was made in the 1970s.

Function

The double-helical configuration that DNA strands naturally reside, makes them difficult to separate and yet they must be separated by helicase enzymes, if other enzymes are totranscribe the sequences that encode proteins, or if chromosomes are to be replicated. In so-called circular DNA, in which double-helical DNA is bent around and joined in acircle, the two strands are topologically linked, or knotted. Otherwise identical loops of DNA, having different numbers of twists, are topoisomers, and cannot be interconverted by any process that does not involve the breaking of DNA strands. Topoisomerases catalyze and guide the unknotting or unkinking of DNA^[2] by creating transient breaks in the DNA using a conserved Tyrosine as the catalytic residue.^[1]

The insertion of (viral) DNA into chromosomes and other forms of recombination can also require the action of topoisomerases.

Clinical significance

Many drugs operate through interference with the topoisomerases [1]. The broad- spectrum fluoroquinolone antibiotics act by disrupting the function of bacterial type II topoisomerases. These small molecule inhibitors act as efficient anti-bacterial agents by hijacking the natural ability of topoisomerase to create breaks in chromosomal DNA.

Some chemotherapy drugs called topoisomerase inhibitors work by interfering with mammalian-type eukaryotic topoisomerases in cancer cells. This induces breaks in the DNA that ultimately lead to programmed cell death (apoptosis). This DNA- damaging effect, outside of its potential curative properties, may lead to secondary neoplasms in the patient.

Topoisomerase I is the antigen recognized by Anti Scl-70 antibodies in scleroderma.

Topological problems

There are three main types of topology: supercoiling, knotting, and catenation. Outside of the essential processes of replication or transcription, DNA must be kept as compact as possible, and these three states help this cause. However, when transcription or replication occurs, DNA must be free, and these states seriously hinder the processes. In addition, during replication, the newly replicated duplex of DNA and the original duplex of DNA become intertwined and must be completely separated in order to ensure genomic integrity as a cell divides. As a transcription bubble proceeds, DNA ahead of the transcription fork becomes overwound, or positively supercoiled, while DNA behind the transcription bubble becomes underwound, or negatively supercoiled. As replication occurs, DNA ahead of the

replication bubble becomes positively supercoiled, while DNA behind the replication fork becomes entangled forming precatenanes. One of the most essential topological problems occurs at the very end of replication, when daughter chromosomes must be fully disentangled before mitosis occurs. Topoisomerase IIA plays an essential role inresolving these topological problems.


Classes

Topoisomerases can fix these topological problems and are separated into two types depending on the number of strands cut in one round of action:^[3] Both these classes of enzyme utilize a conserved tyrosine. However these enzymes are structurally and mechanistically different.

- A type I topoisomerase cuts one strand of a DNA double helix, relaxation occurs, and then the cut strand is reannealed. Cutting one strand allows the part of the molecule on one side of the cut to rotate around the uncut strand, thereby reducing stress from too much or too little twist in the helix. Such stress is introduced when the DNA strand is "supercoiled" or uncoiled to or from higher orders of coiling. Type I topoisomerases are subdivided into two subclasses: type IA topoisomerases, which share many structural and mechanistic features with the type II topoisomerases, and type IB topoisomerases, which utilize a controlled rotary mechanism. Examples of type IA topoisomerases include topo I and topo
 - III. In the past, type IB topoisomerases were referred to as eukaryotic topo I, but IB topoisomerases are present in all three domains of life. Like type II topoisomerases, type IA topoisomerases form a covalent intermediate with the 5' end of DNA, whereas the IB topoisomerases form a covalent intermediate with the 3' end of DNA. Recently, a type IC topoisomerase has been identified, called topo V. While it is structurally unique from type IA and IB topoisomerases, it shares a similar mechanism with type IB topoisomerase.
- A type II topoisomerase cuts both strands of one DNA double helix, passes another unbroken DNA helix through it, and then reanneals the cut strands. This class is also split into two subclasses: type IIA and type IIB topoisomerases, which possess similar structure and mechanisms. Examples of type IIA topoisomerases include eukaryotic topo II, E. coli gyrase, and E. coli topo IV. Examples of type IIB topoisomerase include topo VI. Type II topisomerases utilize ATP hydrolysis.

Topoisomerase	IA	IB	IIA	IIB
Metal Dependence	Yes	No	Yes	Yes
ATP Dependence	No	No	Yes	Yes
Single- or Double-Stranded cleavage?	SS	SS	DS	DS
Cleavage Polarity	5'	3'	5'	5'
Change in L	±1	±N	±2	±2

Both type I and type II topoisomerases change the linking number (L) of DNA. Type IA topoisomerases change the linking number by one, type IB and type IC topoisomerases change the linking number by any integer, whereas type IIA and type IIB topoisomerases change the linking number by two.




04. SELECTION OF LIGAND SKELETON

4.1 Chemistry of Anthracene

Anthracene is a solid polycyclic aromatic hydrocarbon (PAH) of formula C₁₄H₁₀, consisting of three fused benzene rings. It is a component of coal tar. Anthracene is used in the production of the red dye alizarin and other dyes. Anthracene is colorless but exhibits a blue (400-500 nm peak) fluorescence under ultraviolet light Coal tar, which contains around 1.5% anthracene, remains a major source of this material. Common impurities are <u>phenanthrene</u>and <u>carbazole</u>. A classic laboratory method for the preparation of anthracene is by cyclodehydration of o-methyl- or o-methylene-substituteddiarylketones in the so-called <u>Elbs reaction</u>.

It may also occur in the <u>interstellar medium</u>. [9] More than 20% of the <u>carbon</u> in theuniverse may be associated with PAHs, including anthracene. [1]


Anthracene photodimerizes by the action of <u>UV</u> light:



The <u>dimer</u>, called dianthracene (or sometimes paranthracene), is connected by a pairof new carbon-carbon bonds, the result of the [4+4] <u>cycloaddition</u>. It reverts to anthracene thermally or with <u>UV</u> irradiation below 300 nm. Substituted anthracene derivatives behave similarly. The reaction is affected by the presence of oxygen. [111][12]

Reduction of anthracene with alkali metals yields the deeply colored radical anion salts M⁺[anthracene]⁻ (M = Li, Na, K). Hydrogenation gives 9,10-dihydroanthracene, preserving the aromaticity of the two flanking rings.

Chemical <u>oxidation</u> occurs readily, giving <u>anthraquinone</u>, $C_{14}H_8O_2$ (below), for example using <u>hydrogen</u> <u>peroxide</u> and <u>vanadyl acetylacetonate</u>. [13]



Anthracene, a wide band-gap organic semiconductor is used as a scintillator for detectors of high energy photons, electrons and alpha particles. Plastics, such as polyvinyltoluene, can be doped with anthracene to produce a plastic scintillator that is approximately water-equivalent for use in radiation therapy dosimetry. Anthracene's emission spectrum peaks at between 400 nm and 440 nm.

It is also used in wood preservatives, insecticides, and coating materials.

Anthracene is one of the three components (the other two being potassium perchlorate and sulfur) which are used to produce the black smoke released during a Papal Conclave. Derivatives

A variety of anthracene derivatives find specialized uses. Derivatives having a hydroxylgroup are 1hydroxyanthracene and 2-hydroxyanthracene, homologous to phenol and naphthols, and hydroxyanthracene (also called anthrol, and anthracenol)[16][17] arepharmacologically active. Anthracene may also be found withmultiple hydroxyl groups, as in 9,10dihydroxyanthracene.



05. LITERATURE REVIEW

5.1 Antimicrobial Activity:

5.1.1 M. Ashok *et al*¹ (2007) were reported convenient one pot synthesis of some novel derivatives of anthracene 9,11 dione possessing 2-chlorobenzaldehyde moiety and evaluation of their antibacterial and antifungal activities.

All the synthesized compounds were screened for their *in vitro* antibacterial activity against standard strains of *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*, *Klebsiella pneumonia* by disc diffusion method and their antifungal activity against four fungal strains of *Aspergillus flavus*, *Aspergillus fumigatus*, *Candida albicans and Penicillium marneffei* by serial dilution method.

5.1.2 J. D. Akbari *et al*² (2008) were reported synthesis and antimicrobial activity of some new anthracene 9,11 dione derivatives and compounds exhibited significant inhibition on bacterial and fungal growth.

The *in vitro* antimicrobial activity of the synthesized compounds was tested against *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, *Pseudomonas aeruginosa*, and *Candida albicans* using the disc diffusion method.

4.1.3 P. Muthumani $et\ al^3$ (2011) were reported synthesis and antimicrobial activity of some novel pyrimidine derivatives.

Antibacterial activities of the synthesized compounds were evaluated against gram (+) *Staphylococcus aureus* and gram (-) *Klebsilla aerogenes* by measuring zone of inhibition. The antifungal activities of the synthesized compounds were evaluated against *Candida albicans* by disc diffusion method.

4.1.4 A. E. Galil *et al*⁴ (2010) reported antimicrobial activity of 2,6-dibenzylidene-3-methylcyclohexanone.

$$R_1$$

Author concludes that thiazolo pyrimidine and substituted thiazolo pyrimidine moietiesfused to 3-methycyclohexane ring are essential for antimicrobial activities.

4.1.5 V.V. Mulwad *et al* ⁵ (2010) were shown synthesis and antimicrobial activity of 7- methyl-3-(2-oxo-2*H*-benzopyran-6-yl)-5*H*-1, 4-thiazolo-[3, 2-a] pyrimidin-5-one and its derivatives.

Compounds screened for antibacterial activity against *Bacillus subtilis*, *Escherichia coli*. and antifungal activity against *Candida albicans*, *Aspergillus Niger* by cup plate method.

4.1.6 A.E. Galil, E. Amr *et al*⁶ (2009) was reported synthesis and antimicrobial activity of thiopyrimidine and thiazolopyrimidine derivatives.


4.1.7 C. N. Khobragade *et al*⁷ (2009) were reported synthesis and antimicrobialactivity of novel pyrazolo [3,4-d] pyrimidine derivatives.

$$R_2$$
 R_3
 R_4
 R_4

All the compounds of the series were screened for their antibacterial and antifungal activity studies. Substitution of hydroxyl and halo groups emerged as active in both antibacterial and antifungal screening.

4.1.8 M. J. Solanki *et al*⁸ (2011) were reported synthesis and antimicrobial activity of novel pyrazolo [3,4-d] pyrimidine derivatives.

4.1.9 Joshi K. K. *et al* ⁹ **(2009)** were reported the synthesis N-(4-clorophenyl)-6-methyl- 4-aryl-2-thioxo- 1, 2, 3, 4- tetrahydropyrimidine-5-carboxamide derivatives as antimicrobial activity.



4.1.10 Ramesh L. Sawant et al¹⁰(2008) were reported antibacterial activity of 3-benzoyl-

2-oxo/thioxo-1, 2, 3, 4-tetrahydropyrimidine analogues. 5-Acyl-6-methyl-4-substituted-2- oxo/thioxo-1,2,3,4-tetrahydropyrimidines were synthesized by cyclocondensation reaction between appropriate aldehyde, acetoacetate and urea/thiourea in presence of aluminium chloride and hydrochloric acid which upon treatment with benzoyl chloride in presence of aluminium chloride in presence of pyridine in benzene furnish the title

compounds. The compounds have been tested for antibacterial activity against staphylococcus aureus.

$$R_2$$
 R_3
 R_4
 R_5
 R_4
 R_5
 R_4
 R_5
 R_5
 R_4
 R_5
 R_7
 R_7

4.2 Anticancer Activity


Kulakarni S. V et al¹¹ (2009) were reported Design, synthesis and anticanceractivity of 4.2.1 some new pyrimidine derivatives.

4.2.2 O. M. fathalla et al¹² (2010) were reported Synthesis, antibacterial and anticancer evaluation of some pyrimidine derivatives. Activity performed by measurement of Potential 4.2.3 Cytotoxicity by Sulfo-Rhodamine-B stain (SRB) Assay. The various novel pyrimidine derivatives showed significant growth inhibition towards liver cancer cell in comparison to 5-Flurouracil.

- [
- 1	
- 1	
- 1	
- 1	
- 1	


H ₂ N		NH	
	N		CN OH
S		N H	

4.2.4 B. R. Prashantha kumar $et~al^{13}$ (2009) were reported novel biginelli dihydropyrimidines with potential anticancer activity. The synthesized Biginelli compounds were subjected for their *in vitro* anticancer activity against MCF-7 human breast cancer cells.



4.2.5 A.A. Abu-Hashem et al¹⁴ (2011) were reported synthesis and antituomer activities of some new thiazolopyrimidines, pyrrolothiazolopyrimidines and triazolopyrrolothiazolopyrimidines derivatives in vitro ehrlich ascites assay.


4.2.6 C. Jarry *et al*¹⁵ (2008) were reported antileukemia activity of 7-hydroxy-2-substituted-methyl- 5H-oxazolo[3,2-a] pyrimidin-5-one derivatives.



They were tested for their ability to inhibit proliferation in human Bcr-Abl⁺ leukemiacells.

4.3 Antioxidant Activity:

4.3.1 A.Pathak *et al*¹⁶ (2010) were reported synthesis and antioxidant activity of ethyl-5- (substituted phenyl)-7-methyl-3-oxo-3, 5-dihydro-2H-thiazolo (3, 2-a)-pyrimidine-6- carboxylates by invitro free radical scavenging activity using DPPH (2, 2-diphenyl-1- picryl hydrazyl) reduction method.



Among the synthesized compounds above structures showed good activitycompared to the standard.

4.3.2 A.A. Abu-Hashem et al¹⁴ (2011) were reported synthesis and antioxidant activityof thiazolo pyrimidine.

All compounds were tested for antioxidant activity as reflected in the ability to inhibitlipid peroxidation in rat brain and kidney homogenates and rate erythrocyte hemolysis.

4.4 Analgesic and Antiinflammatory Activity

4.4.1 S. A. Khan *et al*¹⁷ (2010) reported synthesis and pharmacological evaluation of newer thiazolo (3, 2-a) pyrimidine for antiinflammatory and antinociceptive activity. Antiinflammatory activity was assessed by the rat paw edema method and antinociceptive activity was evaluated by thermal stimulus technique.

Compounds with an aryl ring substituted with a smaller electron withdrawing group at the fourth position displayed better activity than the other derivatives. Substitutions with a halogen atom at both the aryl rings resulted in increased antiinflammatory activity.

4.4.2 P. Muthumani $et\ al^{18}$ (2010) were reported synthesis and analgesic, antiinflammatory activity of some novel pyrimidine derivatives.


Antiinflammatory activity was measured using the carrageenan induced paw edema in the rats. Paw volume was measured using the mercury displacement techniques with the help of a plethysmometer.

Analgesic activity of the compounds by Eddy's hot plate method was evaluated.

Compounds showed analgesic activity less than the reference standard.

$$C_6H_5$$
 C_6H_5
 C_6H_5
 C_6H_5
 C_6H_5
 C_6H_5
 C_6H_5
 C_6H_5


4.4.3 B. Tozkoparan *et al*¹⁹ (2011) were reported synthesis and antiinflammatoryactivities of some thiazolo [3, 2-a] pyrimidine derivatives.



4.4.4 Ramesh L. Sawant $et \ al^{20}$ (2011) were reported analgesic activity of 2-methylthio- 1,4-dihydropyrimidines. Analgesic activity performed by acetic acid induced Writhing method. Compound 4-chlorophenyl group at fourth position of 1, 4-dihydropymidine and ethyl ester at fifth position showed good analgesic activity. Compound with 4- chlorophenyl group at fourth position of 1, 4-dihydropymidine and methyl ester at fifth position showed lowest analgesic activity.

4.5 Acetylcholinesterase inhibitors:

4.5.1 Hui Zhi $et \ al^{21}$ (2008) were reported design, synthesis and biological evaluation of 3-substituted 5*H*-thiazolo [3, 2-*a*] pyrimidine derivatives as acetylcholinesteraseinhibitors.



R= 4-hydroxyphenyl; R'=methyl; Ar=4-chlorophenyl

Among the synthesized compounds above compound showed good acetylcholinesterase inhibitor activity. The results demonstrate the effectiveness and validity of the virtual screening approach especially of the docking screening approach, and provide a starting point for the development of novel drugs to treat Alzheimer's disease.

4.6 Antihistaminic Activity:

4.6.1 F. M. Awadallah *et al*²² (2008) was shown novel 5H- thiazolo [3,2-a] pyrimidin-5-one derivatives as 5-HT_{2A} receptor antagonists.

Novel 5H-thiazolo [3, 2-a] pyrimidin-5-one derivatives linked through ethylene bridge to various phenylpiperazine groups were prepared for evaluation as 5-HT $_{2A}$ receptor antagonists. Compounds were tested for their antagonist activity on 5-HT $_{2A}$ receptors using inhibition of 5-Hydroxytryptophan (5-HTP) induced head twitches in mice.

IJCR


Pharmacophore modelling study, based on a hypothetical pharmacophore template generated from a set of diverse known active ligands, revealed good fitting of the designed compounds to the generated hypothetical pharmacophore.

4.7 Antiviral activity:

4.7.1 S. F. Mohamed *et al*²³ (2010) were reported antiviral activity of thiazolopyrimidine derivatives.

4.8 Calcium Antagonists:

4.8.1 W. Wiegrebe *et al*²⁴ (1992) were reported thiazolo [3, 2-a] pyrimidine derivatives as calcium antagonists.



Calcium antagonistic activities of these compounds were evaluated in K+-depolarized rataorta.

06. MOLECULAR MODELING

06.1 Molecular Modeling and Computational Chemistry:

Medicinal chemists today are facing many complicated challenges. The most demanding and perhaps the most rewarding one is the rational design of new therapeutic agents for treating human diseases.

The definition currently accepted of what molecular modeling can be stated as "molecular modeling is anything that requires the use of a computer to paint, describe or evaluate any aspect of the properties of the structure of a molecule". Methods used in the molecular modeling are regarding automatic structure generation, analysis of three- dimensional (3D) databases and construction of protein models by techniques based on sequence homology, diversity analysis, docking of ligand. Molecular modeling has widened the horizons of pharmaceutical research by providing tools for finding new leads.




Fig. 6.1 Conceptual Frame in Computer-Aided Drug Design

Thus, today molecular modeling is regarded as a field concerned with the use of all sortof different strategies to model and to deduce information of a system at the atomic level.

On the other hand, this discipline includes all methodologies used in computational chemistry, like computation of the energy of a molecular system, energy minimization *Monte Carlo* methods or molecular dynamics. In other words, it is possible to conclude that computational chemistry is the nucleus of molecular modeling. Identification of biomolecular moieties involved in the interaction with a specific receptor permits to understand the molecular mechanism responsible of its specific biological activity. In turn, this knowledge is aimed at designing new active molecules that can be successfully used as drugs. Due to the fact that simulation accuracy is limited to the precision of the constructed models, when it is possible, computational simulations have to be compared with experimental results to confirm model accuracy and to modify them if necessary, in order to obtain better representations of the system.

06.2 Preparation of Library and Molecular Docking

Library of novel 900 quinazolinone based analogues was prepared on the random basis. During the preparation of library care was taken to avoid the long chain substitution at sixth and seventh position while second, third, fourth and fifth position was mainly focused for substitution. All these analogues were subjected to molecular docking and docking score was observed.

Molecular docking is an efficient tool for investigating receptor-ligand interactions and for virtual screening, which plays a key role in rational drug design, especially when the crystal structure of a receptor or enzyme is available.

It is widely accepted that drug activity is obtained through the molecular binding of one molecule (the ligand) to the pocket of another, usually larger, molecule (the receptor), which is commonly a protein. In their binding conformations, the molecules exhibit geometric and chemical complementarily, both of which are essential for successful drug activity. Molecular docking helps in studying drug/ ligand or receptor/ protein interactions by identifying the suitable active sites in protein, obtaining the best geometry of ligand- receptor complex and calculating the energy of interaction for different ligands to design more effective ligands. Furthermore, the use of a colour code to indicate the nature of the atoms and functional groups present in the three dimensional

structures also enables the medicinal chemist to investigate the binding of the ligand tothe target site.

Molecular mechanics also enables the medicinal chemist to calculate the binding energy of a ligand. This is the energy lost when the ligand binds to its target site, that is

$$E_{Binding} = E_{Target} + E_{Ligand} - E_{Target + Bound \ ligand}$$

All the quantities on the right hand side of the equation may be calculated using molecular mechanics force fields. However, it should be remembered that in many cases the binding of a drug to its target should be weak, because in most cases it has to be able to leave the target after it has activated that site. A major problem with docking procedures is that the conformation adopted by a ligand when it binds to its target site will depend on the energy of the molecular environment at that site. This means that, although a ligand may have the right pharmacophore, its global minimum energy conformer is not necessarily the conformation that binds to the target site, that is:

Global minimum energy conformer → bioactive conformer

However, it is normally assumed that the conformers that bind to target sites will be those with a minimum potential energy. Since molecules may have large numbers of such meta stable conformers a number of techniques, such as the Metropolis Monte Carlo method and comparative molecular field analysis (CoMFA) have been developed to determine the effect of conformational changes on the effectiveness of docking procedures.

Docking procedures have also been adapted to design possible leads. The computer is used to fit suitable structural fragments into the docking area. These fragments are joined to make molecules that fit the docking site. This procedure is referred to as *De novo* design.

The target or receptor is either experimentally known or theoretically generated through knowledge based protein modeling or homology modeling. The molecular docking tool has been developed to obtain a preferred geometry of interaction of ligand - receptor complexes having minimum interaction energy based on different scoring functions viz. only electrostatics, sum of steric and electrostatic (parameters from MMFF force field) and Dock Score. V-Life MDS uses genetic algorithm (GA), Piecewise Linear Pair wise Potential (PLP) and Grid algorithms to minimize the interaction energy between ligand - receptor.


One key aspect of molecular modeling is calculating the energy of conformations and interactions using methods ranging from quantum mechanics to purely empirical energy functions. Molecular docking energy evaluations are usually carried out with the help of a scoring function. Developing these scoring functions is a major challenge in structure based drug design. Efficiency and accuracy of geometric modeling of the binding process to obtain correct docking solutions depends on scoring function. Usually scoring functions are based on force fields that were initially designed to simulate the function of proteins (based on enthalpy).

The Grid based docking is a rigid and exhaustive docking method. In this method, after unique conformers of the ligand are generated, the receptor cavity of interest is chosen by the user and a grid is generated around the cavity (default grid interval size 1 Å). Cavity points are found and the centre of mass of the ligand is moved to each cavity point. All rotations of ligand are scanned at each cavity point where ligand is placed (step size of rotation could be typically 100-150 as an example). For each rotational pose of the ligand is generated and the corresponding bumps are checked for each pose of ligand. The score is calculated for each valid pose (determined by the cut off criteria fed by user in terms of max no of allowed bumps) and the pose of the ligand with the best score is given as output to user. VLife MDS provides a facility to dock different ligands in protein binding sites chosen by the user.

06.2.1 Target structure:

The structure of target was obtained from the protein data bank (PDB code 2W3M and 3FRE). The receptor was in complex with folic acid and trimethoprim.

PDB 2W3M was used for anticancer drug design having total 187 amino acids. VAL 1A and ASP 186B are terminal amino acids in 2W3M. PDB 3FRE was used for anti- microbial drug design having total 158 amino acids. THR 1X and ASP LYS 157X are terminal amino acids in 3FRE.



06.2.2 Methodology and cavity identification:

Docking studies of the prepared library of pyrimidine analogues was done on Vlife MDS 4.3 using Ga and grip based docking method. The crystal structure of DHFR enzyme receptor was obtained from PDB (PDB entry 2W3M and 3FRE). By using V-life MDS, 2W3M and 3FRE was open in MDS sheet and saved as sybale format by removingwater molecule and then this receptor structure was used further for docking purpose.

The 2D structure of the compounds were drawn by using 2D draw molecule option of Vlife and then converted into the 3D by exporting to window of MDS sheet. The 3D structures were then energetically minimized up to the rms gradient of 0.01 using Merck Molecular Force Field (MMFF). Docking methodology is shown in fig. no 6.3





Fig. 6.4 Docking methodology

By click on biopredicta and then open biopredicta tool; goes to cavity determination option from software cavities of receptor were determined. The cavities in the receptor were mapped to assign an appropriate active site, the basic feature used to map the cavities were the surface mapping of the receptor and identifying the geometric voids as well as scaling the void for its hydrophobic characteristics. Hence all the cavities that are present in receptor are identified and ranked based on their size and hydrophobic surface area. Cavity no.1 was selected for docking of PDB 2W3M and 3FRE receptor. Cavity no.1 of 2W3M have volume 17942ų and surface area = 17035.01 Ų which is highlighted in red color in **Fig.6.4**. Cavity no.1 of 3FRE have volume 3205ų and surface area = 4709.06Ų which is highlighted in greenish color in **Fig.6.5**.

The active site for docking was defined as all atoms within 5Å radius. From biopredicta tool open docking and then batch grid docking. Batch docking shows browsing of receptor, ligand (Compound) and result generated saved in output file. Compounds saved in output file as a docked ligand format with proper conformation

which will further use in checking binding interaction. Results generated were saved aslog file in output folder.



06.2.3 Docking results:

Table no. 06.1 Docking score result

Sr.No	Co	Structure	DockScore	SrNo	Comp	Structure	DockScore
	mp				Code		
	Cod						
	e						
1	1r	N N N N N N N N N N N N N N N N N N N	-2.910738	6	1w	N H	-4.724920

2	1s		-4.440204	7	1x		-4.488551
		N N H				N N N N	
		H H				6 H H	
3	1t		-4.660487	8	1y		-4.523380
		N H				P N H	
		J H H					
4	1u	N O	-4.543399	9	1z	N O	-4.429177
		N N				N	
		N N N H				N H	
ŕ						H A	
5	1v		-4.583955	10	2a		-4.323399
		N N H				N N N N N	
	0	H H					
11	01		2.452525	16		C	2 2 4 2 2 7
11	2b	N N	-3.162625	16	2g	N	-3.240237
				,		F	
		N N N					
12	2c	N O	-3.717053	17	2h	N O	-3.729988
		H N → H				N CI	
		P N N H				P N N H	
		\ H H					
	11	l	1		l	l	1

13	2d		-4.658023	18	2i		-3.625920
		N				CI	
		N N N N				N H	
		₩ ₩				H H H	
14	2e		-3.144853	19	2j		-4.445704
		,cı				I CI	
		N N N H				N H	
15	2f		-3.552788	20	2k		-4.128493
	2.	Ů F	5.552765	20	ZK	N O	
		N N N N N N N N N N N N N N N N N N N				N H	
ľ							
21	21	S 0	-3.401577	26	2q		-3.982544
	1	CI				N F	
K	9	H H	\sim 1				
22	2		2.522452	07	2		
22	2m	N G	-2.539450	27	2r	l N I F	-3.936351
		N N N H				N H	
		4 4				l l l	
23	2n		-3.164620	28	2s		-2.644648
		N Cl				F	
		N N N N N N N N N N N N N N N N N N N					
		b				 	

24	2o		-3.350069	29	2t		
		N F					-3.018975
		H H				N O O H	
		Ť				#	
25	2p	N O	-3.579170	30	2u		-2.045620
						H H H	
2.1							
31	2v	N O H	-0.347136	36	3c		-4.267482
		NO H					
						H 0 1	
32	2w	н ⁴ .н	-2.85 <mark>0885</mark>	37	3d		-4.673965
		N O H					
9							k
	S		\sim 1			68	
33	2x	N O O H	-4.216313	38	3e	10.	-4.330076
				1			
		N N N				M d	
		· · · · · · · · · · · · · · · · · · ·					
34	3a	0	-4.179420	39	3f	0	-4.666087
		T II II				A	
						H H	

35	3b		-4.415052	40	3g	0	-4.495306
						o H	
		/				, H	
41	3h	O.	-4.972067	46	3m	, o	-3.877454
		F					
42	3i	0	-4.816826	47	3n	0	-4.084500
						N N	
						N N	
		, ,				4 8 н	
43	3j		-3.713055	48	30		-3.825821
	<i>5</i> j	, H	3.713033		30		0.023021
9		H					
R		H H		N		, ,,,	. *
	M						
44	3k		-4.937042	49	3p	Î	-2.954136
		ا ا					
45	31	0	-4.799076	50	3q		-4.157927
		H H				HHH	
						н	

51	3r	0	-4.325091	56	3w	-4.320418
52	3s		-4.477919	57	3x	-4.520437
53	3t		-4.454208	58	3y	-4.515141
54	3u	0=	-4.887077	59	3z	-4.398973
,						
55	3v		-4.777392	60	4a	-3.552788
	3		4.77732			
61	4b		-4.128493	66	4g	-3.401577

62	4c		-3.982544	67	4h	o	-2.539450
		N N N					
63	4d	5	-3.936351	68	4i		-3.164620
		N N N					
64	4e		-2.644648	69	4j	Ħ, II	-3.350069
		H					
65	4f		-3.018975	70	4k		-3.552788
R	0		<u> </u>				
71	41		-4.415052	76	4r	10.	-4.128493
						S H	
						A H	
72	4				4		
72	4n	H	-4.972067	77	4s	N H T	-3.982544
		N N				N H	
		/ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				<	

73	4o		-4.816826	78	4t		
		HHHH				N H H	-3.936351
						N N O	
74	10		-3.713055	79	4u		-2.644648
74	4p	The state of the s	-5./15055	19	4u	N H H H	-2.044046
75	4q		-4.937042	80	4v		
	.4					F F	-3.018975
Ė	4						
81	4w		-4.799076	86	5b		-3.169153
1							
82	4x		-4.325091	87	5c		-2.477860
		N N N N N N N N N N N N N N N N N N N					
83	4y		-4.415052	88	5d	a	-2.768214
						CI N N N N N N N N N N N N N N N N N N N	

84	4z		-4.972067	89	5e		-2.244581
		H H					
		N N N) H	
0.5			2 204440	00	7.5		1.501610
85	5a		-3.301119	90	5f		-1.591610
91	5g		-0.625637	96	5m		-0.519627
	4						
	=		A.				,
92	5i		-2.872770	97	5n		-1.859843
{			$\langle \gamma \rangle$				
	M					122	
93	5j		-3.110456	98	50		0.335012
94	5k		-1.827941	99	5p		-4.685366
7-7	JK	H H	1.02/341		υP	CI	7.005500
		N N N				N N N	

95	51	Ÿ.	-1.248823	100	5q	_ н	-3.879674
101			-2.424660		5w	F N O	-2.427473
102	5s		-3.419863	107	5x	F CI	-4.291121
103	5t		-3.412892	108	5y		-3.897591
) (7				
104	5u	793 /	-3.704842	109	5z		-1.996366
105	5v		-2.882619	110	ба		-1.750336

111	6b	. 4	-4.279670	116	6g	Н	0.169404
112	6с		-1.333442	117	6h		-0.919442
113	6d		-2.966944	118	6i		-3.524908
114	6e		-3.663190	119	6j		-3.011446
115	6f		-3.088192	120	6k	A DO H	-3.127130
121	61		-3.362113	126	6q	H H H H	-3.436488

122	6m		-2.066932	127	6r		-3.994591
123	6n		-3.784437	128	6s		-3.401185
124	60		-2.535225	129	6t	N N N N N N N N N N N N N N N N N N N	-4.267917
125	бр		3.905382	130	би		-2.853757
131	6v	H	-3.960534	136	7a		-3.858939
132	6w		-4.507489	137	7b	S H	-4.677759

133	6х		-4.116265	138	7c		-4.988944
133	UA	Q H	-4.110203	136	70	 	-4.988944
		H					
						S	
		N N NO				ji d	
		H				ų u	
134	6у	0	-3.567000	139	7d	N. v. v.	-4.917652
						CI	
135	6z		-3.161491	140	7e		-5.110830
		a de la companya de l					
			$\sqrt{1}$			5	
		N N O				"	
						CI CI	
141	7f		-4.421368	146	7k		-4.620093
171	/1	N-1 1	4.421300	140	/ K		4.020033
-							/ /
		H \					<
142	70		-2.968208	147	71		-4.536653
142	7g		-2.500200	14/	/1		-4.330033
				1			
				-		s A	
		H 0=N				H O H	
		6				I H	
143	7h		-4.805094	148	7m		-3.498650
						, , , , , , , , , , , , , , , , , , , ,	
		N 0				H H	
						H	

144	7i		-4.167589	149	7n	N- v	-3.801332
		5 H					
145	7j		-4.976487	150	70	H H	-3.268297
151	7p		-3.697325	156	7u		-4.655070
152	7q		-4.269085	157	7v	440	-4.043108
153	7r		-3.586099	158	7w		-2.846323
154	7s		-4.382877	159	7x		-3.217989

155	7t	N-v u	4.225026	160	7y	<i>‼</i> —н »	-4.019805
		H H				H H	
161	7z	N- N- N	-3.826260	166	8e	N−n n	-3.800268
		S					
162	8a		-4.232711	167	8f		-4.442810
						F	
						S N H	
	_3					/ 4	
163	8b	/-\ /	-4.067793	168	8g	N-N N	-3.826260
	<u>بر</u>					S	
B	2						
164	8c		-4.098886	169	8h	, n	-3.916886
						S	
		Н					
165	8d	<i>)</i> -\\	-3.603106	170	8i	H	-3.323989
		CT H					
		H H				H	

171	8j	-4.761317	176	80		-3.084180
	S N C C C C C C C C C C C C C C C C C C				S	
172	8k	-5.166939	177	8p		-4.255596
173	81	-4.404545	178	8q		-4.387368
174	8m	-4.280534	179	8r		-4.469692
175	8n	-4.525994	180	8s		-3.793916
181	8t	-3.675090	186	8y		-4.447327

182	8u	н	-3.105673	187	8z		-3.891052
		H 11					
183	8v		-4.384169	188	00		-3.245943
183	8V	H N	-4.384109	100	9a	, n	-3.245943
						H	
184	8w		-4.154047	189	9b		-3.114417
	0,,,	Y Z Z		10)	, ,		0.222
		H	$\sqrt{1}$				
						I w	
185	8x	*	-3.511585	190	9c		-2.750001
4			_	,			
1.5	. 0		$\overline{}$				
101	0.1	. 63 7	4.507430	106	0::		2.004670
191	9d		-4.507438	196	9r		-2.994679
						H N N	
		F H				S N F	
		H				<i>y</i> ~ ·	
192	9n		-4.955722	197	9s		-5.142680
1,72	/11	H	1.555722	171	73		3.1 12000
		N				H 'O	
		H					
						<i></i>	
							l I

102	Os		2.000062	100	04		F F4C2C7
193	90	O _H	-2.900063	198	9t		-5.516267
		H					
						H	
						5 N F	
		<i>∅</i> ~ o					
194	9p		-4.727034	199	9u		-5.395847
174)P	OH	-4.727034	1//	Ju		-3.333647
		H				HN	
		s N F				N N	
		4					
		,					
195	9q	7	-4.318144	200	9v		-2.734596
		H			⁻		
						H	
	7						
	-					, , , , , , , , , , , , , , , , , , ,	
201	0		2 4 4054 4	206	10		2 4 452 45
201	9w		-3. <mark>148514</mark>	206	10q		-2.145345
						N H	
		× +					
) T
202	9x		-3.469140	207	10r		-3.505604
						NNN S	
		N I					
		H H					
203	9y		-3.13937	208	10s	^^	-3.915887
						N = 8	
		N N N					
		√ <u></u>					

204	9z			-3.139378	209	10t	N	-4.092397
		H						
		L H						
205	10p	°		-3.826260	210	10u		-3.898161
		N N N						
							H H	
211	10v	N		-3.409820	216	11a	$\mathring{\bigcirc}$	-2.025605
						*		
		W H		\mathbb{K}^{2}				
		Ę					a	
212	10w			-3.900422	217	11b	6	-3.468556
-		N H						
3	9			— 1				
213	10x		1	-3.692035	218	11c		-3.836262
		N N N N N N N N N N N N N N N N N N N					N N N N N N N N N N N N N N N N N N N	
							*	
		Ęı					Ę,	
214	10y	ightharpoonup		-3.112414	219	11d		-3.119516
		N N N N N N N N N N N N N N N N N N N						
		Sel					Ü	

215	10z	<u></u>		-2.133289	220	11e	-3.241220
221	116				226		
221	11f			-4.178061	226	11k	-4.186499
222	11g	,		-3.398930	227	111	-3.639210
				F			
<u> </u>	_	Ţ—"				11	
223	11h	N		-4.303102	228	11m	-1.873283
3	· ~		1				
224	11i			-2.905795	229	11n	-3.061712
225	11j			-2.623271	230	110	-1.993729

231	11p		-3.175018	236	11u	N	-3.406342
	r	N N					
		N N N N N N N N N N N N N N N N N N N					
		H				H	
232	11q	<u>~</u>	-3.095412	237	11v	^0	-2.923298
						8	
222	1.1		2 444224	220	1.1		0.101700
233	11r		-3.441934	238	11w		-2.191706
		H				N N	
		a					
234	11s	N	-2.716310	239	11x		-2.072358
			=				,
		H 1					
4		L.					
			$\overline{}$			100	. *
235	11t		-3.054501	240	11y		-2.285122
				1			
						N	
241	11.		2.270022	246	10-		2.407000
241	11z	N	-2.279922	246	12e		-3.187980
		N N					
						H 11	
		нн				l.	

242	12a	"N	-1.573313	247	12f	, N.	-2.644202
						N	
		H—H				H H H	
				2.10			
243	12b	N	-1.833354	248	12g	l N	-2.934447
						N The Ch	
		н				H	
		L L				, L	
244	12c		-2.064308	249	12h		-2.637720
						N	
			\mathbb{Z}				
		" "				H	
245	12d		-2.10 <mark>5344</mark>	250	12i		-3.800956
243	120		-2.105344	230	121		-3.800956
						N V	
9							
1.5		H H	$\overline{}$			//8	. *
251			ا ل	2			
251	12j	N	-3.456698	256	12o	<mark>)</mark> н	-4.022775
				-		HNHH	
						N	
						S H	
		E				I The state of the	
252	101-		2 250257	257	10		4 200074
252	12k	N	-3.350357	257	12p	I A A	-4.206974
						H N H	
						N N	
						S N CI	
		F.					
]

253	121	٥.	-4.152246	258	12q		-4.568143
						, H	
						N N	
						s H	
		<u>. </u>					
254	12	الر ال	-2.061378	259	12r	l H	-3.616094
	m	HNHH				H	
		N				N F	
		H W					
255	12n		-3.951177	260	12s		-4.754674
					1	H. H.	
						N CI	
						1/ 11	
261	13a		-5.010238	266	13f		-5.605707
						Y Y	
		N H				N N	
5	~						
	Ĉ	N H					
262	13b	N H	-3.470235	267	13g		-5.027274
262	13b		-3.470235	267	13g		-5.027274
262	13b		-3.470235	267	13g		-5.027274
262	13b		-3.470235	267	13g		-5.027274
262	13b		-3.470235 -3.043348	267	13g		-5.027274 -4.536766

264	13d		-4.767730	269	13i		-5.038153
		N H				H C C C C C C C C C C C C C C C C C C C	
265	13e		-2.988729	270	13j	N H	-5.303599
271	13k	8	-5.199943	276	13p	NA II	-3.244580
		N H					
272	131	N. II	-3.770917	277	13q	N. I	-4.789086
	(9)						
273	13	0	-4.117012	278	13r		-2.844033
	m					H H O H H H	
274	13n	N H	-4.821770	279	13s		-3.833987

275	13o		-4.239513	280	13t		-4.113904
		H H					
281	13u		-4.487984	286	13z	H N H	-5.115248
282	13v		-3.675171	287	14a	N H	-4.804716
283	13w	H H	-3.925524	288	14b		-5.138929
284	13x		-4.244718	289	14c	N H	-4.759625
285	13y	N H	-3.826260	290	14d	N H	-4.207575

291	14e		-4.637284	296	14j	-4.843097
		N H			N H	
		N			N N	
		Н				
292	14f		-4.365852	297	14k	-4.949817
		N H			N H	
		, in the second				
293	14g		-4.950690	298	141	-4.336707
273	175	N J H	4.550050	270	N H	4.550707
			\L/		N	
294	14h	N H	-4.298543	299	14m	-4.396033
		N H				
3		h h				
(3)					C	
295	14i		-4.174539	300	14n	-4.017758
		N H			N H	
		N N			N H	
301	14o	N ₂ II	-4.501035	306	14t	-3.709904
		N H			N H	
		J H				

302	14p		-3.965385	307	14u		-4.421953
		N H				N H	
		, i				H	
303	14q	0	-3.098552	308	14v	Q	-4.757928
		N H				N H	
		N S				S	
		H H					
304	14r		-4.116758	309	14w		-4.855990
		N. I				N H	
						N S	
		N N S				c H	
305	14s		-3.78 <mark>4990</mark>	310	14x		-3.779552
		N H					
		N S				c V V S	
	0					/0	
311	14y	765 N	-4.577943	316	15d	1.0	-4.374582
		N H					
		N S		-		H T CO	
		H H				H H	
312	14z		-4.452018	317	15e	ρ	-4.815258
		N H				N N N N N N N N N N N N N N N N N N N	
		N S				8	
		Ĥ				"	

313	15a		-3.978815	318	15f	_	-4.736611
		H o H					
		H H					
314	15b		-2.180296	319	15g	N	-4.539414
		H H					
315	15c	Q.	-4.023810	320	15h		-4.609531
						N H	
		H				, I	
		H H				L _I	
321	15i	0	-4.253608	326	15n		-4.492146
		N H	Ţ			N H	
5							
322	15j	N H	-4.121126	327	15o	N H	-4.219796
		H				H H	
323	15k	N	-4.309135	328	15p		-3.672766
		"				H	
		H				I I	
1			1				

324	151		-4.996218	329	15q	0	-3.314897
		N H				H	
		N S					
		ધ				HT A	
325	15	N. OI	-4.498693	330	15r	N. J	-2.524178
	m					H H H	
		S N				" "	
		ļ.				H—— H	
331	15s		-4.121758	336	15x		-4.163085
		H				H	
						1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		1				H 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
332	15t		-3.797939	337	15y		-4.393760
		N H	=				
						E THE STATE OF THE	
	بخو	H					
333	15u		-2.837024	338	15z		-4.760165
333	13u	Ů H	-2.837024	336	132		-4.760165
		H N S				H	
						CC H H	
		% • • • • • • • • • • • • • • • • • • •					
334	15v	0	-3.160562	339	16a		-4.200825
		N H				N H	
		H				N	
		0=N				H H	

335	15w		-3.832342	340	16b	0	-4.340673
						H H	
341	16c		-4.052493	346	16h	N H H	-4.954228
342	16d		-4.277469	347	16i	N H	-4.372262
343	16e		-4.310887	348	16j		-4.364820
344	16f		-4.226657	349	16k	N H	-4.277987
345	16g	H H	-4.274318	350	161	N H	-4.225955

351	16		-4.883423	356	16r		-4.963976
	m	N H					
352	16n	CL	-4.385979	357	16s	CIN	-3.308057
353	160		-4.825975	358	16t		-4.896991
354	16p		-4.325259	359	16u		-3.797137
355	16q		-4.591886	360	16v		-2.373918
361	16w	H H	-3.973661	366	17b		-4.315891

362	16x	0	-4.020432	367	17c	0	-3.588071
						C	
					F		
363	16y	C	-4.517252	368	17d	cL L.	-4.011337
					F		
364	16z		-2.509477	369	17e		-4.104365
		N				C N	
					"		
365	17a		-4.244486	370	17f		-3.573649
			—			C N	,
371	17g		-3.618258	376	171	108	-0.140281
		H	والسا			Y. TN	
		cr H		1		H H H	
						A.	
372	17h	0	-2.559690	377	17m	° II	-2.294390
		H N				H	
						H	
		-				r H a	

373	17i	,	-3.435336	378	17n		-3.879006
		C N				4	
						#	
						H_ F	
374	17j	°	-3.358095	379	17o		-3.067478
		, , , , , , , , , , , , , , , , , , ,					
						H	
375	17k		-3.892049	290	170		-3.745782
373	1 / K		-3.892049	380	17p		-3.743782
			$\perp \langle \rangle$				
						o=N	
201	1.77			20.6	17		
381	17q		-4.423487	386	17v		-4.168869
381	17q		-4.423487	386	17v		-4.168869
381	17q		-4.423487	386	17v		-4.168869
	()						
381	17q 17r		-4.423487 -3.252190		17v		-4.168869 -3.173607
	()						
	()						
	()			387			
382	17r		-3.252190	387	17w		-3.173607
382	17r		-3.252190	387	17w		-3.173607

384	17t			-3.289984	389	17y		-3.810869
		CL					H CC	
		H H						
385	17u	cı L		-3.767748	390	17z	a Å	-4.436007
		H H N					H	
391	18a	Ŷ		-3.695127	396	18f		-4.247932
		CL						
	\leq	H						
202	1.01-			4 4 0 4 4 6 7	207	10-		4 522404
392	18b	a Î		-4.181167	397	18g		-4.523481
-								
15	0		T	~ 1			, o d	
	W		- \	با			10"	
393	18c	•		-3.352344	398	18h	13	-2.345411
		C N					H	
		H O N						
		Н					н . н	
394	18d			-3.498106	399	18i		-4.189879
	104	CLN		000200		101	C	
		N						
		H						

395	18e			-4.529960	400	18j		-4.445924
		CL						
		N						
		"S \\						
							<u> </u>	
401	18k			-4.724231	406	18p		-3.824216
		cı L			.00	1 ° P		
							H 0	
							H \	
402	181			-4.444359	407	18q		-2.264583
		cı 📗						
403	18			-5.020778	408	18r		-3.489998
.05		CI -		3.020776	400	101		3.483338
	m			3.020776	400	101		3.469396
				3.020770	400	101		3.483336
			Y	3.020778	400	101		3.483336
	m		Y					
404			Y	-4.153705	409	18s		-3.852945
	m							
	m							
	m							
404	m 18n			-4.153705	409	18s		-3.852945
	m							
404	m 18n			-4.153705	409	18s		-3.852945
404	m 18n			-4.153705	409	18s		-3.852945
404	m 18n			-4.153705	409	18s		-3.852945

411	18u		-2.851790	416	18z		-3.628209
		C				c N	
	1.0						
412	18v		-2.896163	417	19a	l M	-3.059796
		H					
						H /4	
413	18w	0.	-3.479045	418	19b	O AN	-4.473963
		C					
						*	
414	18x		-3.487054	419	19c		-3.806633
5							
1	S		$\overline{}$				
415	18y	. 63	-3.898279	420	19d	10.	-3.352320
713	10 y	C N	-3.038273	720	170		-3.332320
		N					
421	19e		-3.030760	426	19j		-4.306638
721	170	C N	3.030700	720	1)	I H	4.500050
						H H	

422	19f		-4.832666	427	19k	-4.869977
					F	
423	19g		-4.379154	428	191	-5.069025
423	l)g		-4.373134	420	CI	-3.005023
424	19h		-4.466372	429	19m	-4.799637
	4					
425	19i	Ţ	-4.75 <mark>6878</mark>	430	19n	-4.368801
E	· ($\langle \gamma \rangle$			
431	19o		-4.063650	436		-4.521274
432	19p	٥٫	-4.399793	437	19u	-2.700225

19q		-4.616288	438	19v	-3.377177
	5			S H	
19r	H T H	-4.798136	439	19w	-4.286165
19s		-4.865306	440	19x	-4.480608
				, , , , , , , , , , , , , , , , , , ,	
4					
19y		-4.043732	446	20d	-4.621195
Ĝ	F				R
107	- V	4 542216	117	200	-4.572921
192		-4.542510	447	206	-4.572921
20a		-3,813542	448	20f	-4.214630
200		3.013342	770	201	7.214030
	19r	19s 19s 19s	19s -4.865306 19y -4.043732 19z -4.542316	19r -4.798136 439 19s -4.865306 440 19y -4.043732 446 19z -4.542316 447	19s -4.865306 440 19x 19y -4.043732 446 20d 19z -4.542316 447 20e 20a -3.813542 448 20f

444	20b		-2.582441	449	20g		-5.165221
		N N N N N N N N N N N N N N N N N N N				N Cl Cl	
445	20c		-3.656295	450	20h	o /\range cl	-4.729979
451	20i		-3.974683	456	20o		-3.855503
			3.3.	.50	200		
			\angle				
452	20j		-2.985790	457	20p		-4.446892
- 3	6						
						C	h
453	20k		-5.041253	458	20q		-3.661193
454	201	H H	-3.985512	459	20r	0. 1/	-4.167859

455	20n		-4.366531	460	20s	0	-4.169955
		, , ,				N=0	
461	20t		-4.532674	466	2011		-4.434250
401	201	, ,=0	-4.532074	400	20y	0	-4.434250
462	20u	٥,	-3.927186	467	20z	_ CI	-4.953069
							/ /
463	20v	,0	-5.381429	468	21a		-5.451107
1 5							
	A					F 3.3	
1.5.1	20			1.50	241	100	
464	20w		-4.037913	469	21b	<u></u>	-4.173151

465	20x		-5.027669	470	21d		-3.489084
		F				No. I H	
471	21e	H 1 7	-3.777815	476	21j	0	-2.964029
472	21f	1	-4.540665	477	21k		-1.541666
			L/				

473	21g		-4.699584	478	211		-3.390888
	94						
K	9		71			R	
474	21h		-2.571406	479	21n		-3.211257
				1			
						"	
475	21i	6 K ⁰	-3.851771	480	21o	∠ ^{Cl}	-3.635492
						H	
		H H				, in	
		* ~ _					

481	21p		-3.814499	486	21v	-4.897347
		, H				
482	21q	~ ^F	-4.411104	487	21w	-4.545979
483	21s		-4.543544	488	21x	-4.428000
			/5			
	\preceq					
484	21t		-3.47 <mark>3671</mark>	489	21y	-4.848165
1 3	9				CS	
485	21u		-3.719105	490	21z	-4.291311
491	22a	н	-4.155883	496	22f	-2.490990

492	22b		-3.989309	497	22g	н	-3.775685
		N H H					
		<u>\</u> 6					
493	22c		-4.439062	498	22h	,0	-3.596124
		N					
494	22d	H	-3.813569	499	22i		-3.566322
		No.				F	
						<u></u>	
495	22e		-3.974473	500	22j		-4.297402
		H H	\forall				,
		H					
9				,			
501	22k		-3.696623	506	22p	CH	-4.030095
	X						
				-			
502	221		-2.943893	507	22q	, "H	-3.393188
						The state of the s	
						*	

503	22	, ^{tt} ,#	-4.710402	508	22r	H H A	-2.371625
	m						
504	22n		-3.658821	509	22s		-2.411016
505	220		-4.619071	510	22t		-4.072938
511	22u		-4.363696	516	22z		-3.744416
512	22v	P F	-4.537205	517	23a		-4.705937
513	22w		-3.770509	518	23b		-4.294594

514	22x		-4.219503	519	23c	-4.367162
					F F	
515	22y		-3.399786	520	23d	-4.947393
521	23e		-4.152484	526	23j	-3.648274
522	23f	Н	-3.908731	527	23k	-4.685674
	~		()			
523	23g		-4.496275	528	231	-3.523343
524	23h		-3.452507	529	23m	-4.831431

525	23i	ë, H	-3.648274	530	23n	-5.117128
531	230	The state of the s	-3.738986	536	23t	-4.443023
	23p	N N N N N N N N N N N N N N N N N N N	-3.588666	537	23u	-5.001136
533	23q		-4.893181	538	23v	-4.004928
	23r		-4.376683	539	23w	-3.776627
535	23s		-4.826947	540	23x	-4.085705

541	23y		-4.671801	546	24d	н	-3.948968
542	23z		-4.930937	547	24e		-3.528301
542	LJL	N. F	4.550557	347	240	, , , , , , , , , , , , , , , , , , ,	3.320301
		F					
7.10	2.4			7.1 0	2.46		
543	24a		-5.298300	548	24f	P H	-3.768958
		CI				F	
544	24b	, 1, 1	-3.540991	549	24g		-4.771296
	بخو						
	0		<u></u>				
545	24c		-3.472930	550	24h	C	-3.334928
543	240	, , , , , , , , , , , , , , , , , , ,	3.472330	330	2411		3.334320
551	24i		-3.083847	556	24n		-4.389894
						, H	
						CI	

552	24j		-4.938613	557	24o		-5.185836
						, , , , , , , , , , , , , , , , , , ,	
553	24k		-4.083544	558	24p		-4.605250
555	2-1K	H H	4.003344	330	2-тр		4.003230
		N N N N N N N N N N N N N N N N N N N					
554	241		-3.800076	559	24q		-4.256575
		NS 0 H			4		
		H H	\perp				
,							
5.5.5	2.1			7.00	24		
555	24	н—н	-3.70 <mark>7378</mark>	560	24r		-4.460067
	m						/
1							
						CM	
561	24s	0.8	-4.239809	566	24x		-5.361789
						N CI	
562	24t) U==0	-4.757816	567	24y	a //ci	-5.208916
		N N N					
1							

563	24u		-4.314096	568	24z		-4.480782
						N F	
564	24v		-4.127716	569	25a	, C	-4.031556
565	24w		-4.941881	570	25b	o Cl	-4.573412
		L CI				CI	
			\perp				
571	25c	C C	-4.376011	576	25h	, , , , , , , , , , , , , , , , , , ,	-4.005055
		F	Ų))
							<
572	25d		-4.360790	577	25i	1. 18	-2.146753
		N F					
				1			
573	25e	, F	-4.029074	578	25j	., Ң. н	-4.293033
						N. I	
		b					
	<u></u>						

574	25f		-4.970501	579	25k		-4.419879
575	25g		-4.753556	580	251		-3.276612
581	25 m		-3.607952	586	25s	H H	-4.526787
ć	\leq						
582	25n	٥	-5.239381	5 87	25t		-4.646255
3	9						
583	250		-4.182586	588	25u		-2.783135
584	25p	N N N N N N N N N N N N N N N N N N N	-3.645363	589	25v	H st	-3.744488

585	25r		-2.906897	590	25w	-4.812243
		NS I			F	
591	25x	a (l	-4.526787	596	26c	-3.749750
		N H				
592	25y		-4.812243	597	26d	-4.827365
			VI/			
593	25z	0, 19	-3.577 <mark>975</mark>	598	26e	-3.599957
			_			
3		Ĭ3				
594	26a		-3.541892	599	26f	-4.884792
					i	
595	26b	Ï.	-4.577439	600	26g	-4.152048
		N H				
		"				

601	26h		-4.792261	606	26m	P	-2.614226
		H H				L C L L L L L L L L L L L L L L L L L L	
						H H H	
602	26i	Ч.,н	-3.813652	607	26n	ů N	-4.376821
603	26ј		-3.889632	608	26o	O O	-4.250826
			N.D.			F H	
	\equiv						
604	26k	0	-3.903588	609	26p		-3.788779
	- 6	C T T				CL N	
5		N S					
(3	S					CN	
605	261	0	-4.189697	610	26q	7,3	-4.657095
		C H		-		CL H	
		H_0 S				S S	
		H [*] H					
611	26r		-4.532080	616	26w	0	-3.534443
		CL H				CL H	
						N S	

613 26t -4.416054 618 26y -4.260864 614 26u -4.435655 619 26z -3.347567 615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634	612	26s	0	-4.621198	617	26x	,	-4.284106
614 26u -4.435655 619 26z -3.347567 615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634			CI N H				N H	
614 26u -4.435655 619 26z -3.347567 615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634								
614 26u -4.435655 619 26z -3.347567 615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634								
615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634	613	26t	Ŷ	-4.416054	618	26y	ů	-4.260864
615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634			CL H					
615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634			H					
615 26v -3.756515 620 27a -4.614666 621 27b -4.399317 626 27g -3.819634	614	260		4.425655	610	267		2 247567
621 27b -4.399317 626 27g -3.819634	014	20u	CL N H	-4.435055	019	20Z	I CLAND	-3.34/50/
621 27b -4.399317 626 27g -3.819634			N S			*		
621 27b -4.399317 626 27g -3.819634			o_N				н	
	615	26v	9	-3.756515	620	27a		-4.614666
				=			C H	, ,
	3							
622 27c -4.398298 627 27h -4.383648	621	27b		-4.399317	626	27g		-3.819634
622 27c -4.398298 627 27h -4.383648			C H				C H	
622 27c -4.398298 627 27h -4.383648			N S		***************************************			
622 27c -4.398298 627 27h -4.383648								
	622	27c	o II	-4.398298	627	27h	9	-4.383648
			C H				C H	
							н _Н	

623	27d		-3.932794	628	27i		-3.642334
						F S	
		H H				н	
624	27e		-3.744478	629	27j	C H	-3.320933
625	27f	H H H H	-2.694047	630	27k	H H	-2.570182
631	271		-1.997263	636	27q		-4.548842
632	27 m	N H	-4.107092	637	27r		-3.145629
633	27n	F H	-4.512031	638	27s	F N S	-4.376312

634	27o		-3.549612	639	27t		-4.320038
635	27p	F H H	-1.450219	640	27u		-3.575643
641	27v		-3.999520	646	28a	o o	-3.528582
f						F N H	
642	27w		-3.73 <mark>6955</mark>	647	28b		-4.023002
	(0)						
643	27x	=	-4.714758	648	28c		-4.076359
						H H H	
644	27y		-3.554367	649	28d	F N H	-4.340799

645	27z		-4.348613	650	28e	-4.280205
		F H			F H	
651	28f	H H	-3.647519	656	28k	-4.083017
652	28g	F H	-3.434944	657	281	-4.057068
						the contract of the contract o
653	28h		-4.464760	658	28m	-3.750700
654	28h		-4.464760 -2.044507	658	28m	-3.750700 -4.460118

661	28p		-2.279922	666	29e	0 0	-4.523380
		N=O N H					
		8					
662	29a	0 0 1 1	-1.573313	667	29f	Ŷ	-4.429177
		N N N N N N N N N N N N N N N N N N N					
		N N N					
						H H	
663	29b		-1.833354	668	29g	0 0	-4.323399
					"		
		V	A				
664	29c		-2.064308	669	29h		-3.240237
q		H					
665	29d	257	-2.105344	670	29i		-3.729988
	M						
				-			
671	29j		-3.456698	676	29o		-3.625920
		4 + 4 *					

672	29k		-3.350357	677	29p		-4.445704
673	291	0	-4.152246	678	29q	0 8 H	-4.128493
674	29		-2.061378	679	29r	0 0	-3.982544
	m						
ŀ	\preceq						
675	29n		-3.951177	680	29s		-3.936351
681	29t		-5.010238	686	29y		-2.644648
682	29u		-3.470235	687	29z		-3.018975
		Ť				, and the second	

683	29v		-3.043348	688	30a		-2.045620
						H O	
684	29w		-4.767730	689	30b		-4.267482
685	29x	•	-2.988729	690	30c	0 0	-4.673965
	4) - -			H H	
691	30d		-5.199943	696	30i		-4.330076
	3(0)) (7				
692	30e		-3.770917	697	30j	10	-4.666087
						H	
693	30f	0 0	-4.117012	698	30k		-4.495306
						N S S	

694	30g		-4.821770	699	301	-3.877454
695	30h	н	-4.239513	700	30m	-4.084500
		H S S S S S S S S S S S S S S S S S S S			H H H	
701	30n	0	-4.487984	706	30s	-3.825821
		H O N S	E			
		н "				
702	30o	9 9	-3.675171	707	30t	-2.954136
1 4	0				//0	
703	30p		-2.910738	708	30u	-4.157927
					H	
704	30q	Q Q	-4.440204	709	30v	-4.320418

705	30r	-4.660487	710	30w	-4.520437
711	30x	-4.543399	716	31c	-4.515141
712	30y	-4.583955	717	31d	-4.398973
713	30z	-3.162625	718	31e	-3.552788
714	31a	-3.717053	719	31f	-3.401577
715	31b	-4.658023	720	31g	-2.539450

721	31h		-3.144853	726	31n	-3.164620
		O S S S S S S S S S S S S S S S S S S S			N N N N N N N N N N N N N N N N N N N	
		H				
722	31i		-3.552788	727	310	-3.350069
		, , ,				
		N O				
723	31j	9 9	-3.401577	728	31p	-3.552788
	1					
	4					
	241					
724	311	Q Q	-2.539450	729	31q	-4.128493
		N N N				
B	9		— 1			
725	31		-3.164620	730	31r	-3.982544
	m				الله الله	
					h h	
731	31s	Q Q	-3.350069	736	31w	-3.936351
		N N N N N N N N N N N N N N N N N N N			H N N N N N N N N N N N N N N N N N N N	
		0 "			H, JH H	

732	31t		-3.579170	737	31x		-2.644648
733	31u		-0.347136	738	31y		-3.018975
734	31v		-2.850885	739	31z		-3.169153
E		H H H				H H H	
735	31v	0 0	-4.21 <mark>6313</mark>	740	32a		-2.477860
	~						
741	32b		-4.179420	746	32g		-2.768214
742	32c	H H H	-4.415052	747	32h	H H H	-2.244581

743	32d		-4.972067	748	32i		-1.591610
						N H H	
						H H	
		H H H				H I	
744	32e		-4.816826	749	32j		-0.519627
						N H H	
		H H				H	
		H H H				H H	
745	32f		-3.713055	750	32k	, P t	-1.859843
		H N				N S	
-	-						
751	321	, F	-4.937042	756	32q		0.335012
			V			N H	
		N %5				N S	
		0=1				, ,	
K	0		<u></u>			0	
752	32		-4.799076	757	32r		-4.685366
	m						
		o, S		-		N S S	
7.70	22			5. 50	22		
753	32n	N H	-4.325091	758	32s	N H	-3.879674
		N S				H	
		# H				H N H	
		Н				н	
1		1				l	1

754	32o		-4.477919	759	32t		-2.427473
	320		4.477313	737	320	H H	2.42/4/3
755	32p	N H H	-4.454208	760	32u		-4.291121
761	32v		-4.887077	766	33a		-3.897591
762	32w		-4.777392	767	33b		-1.996366
763	32x	N N N N N N N N N N N N N N N N N N N	-4.128493	768	33c	N N N S S	-1.750336
764	32y		-3.982544	769	33d		0.169404

765	32z	-3.936351	770	33e	-0.919442
771	33f	-2.644648	776	33k	-3.524908
772	33g	-3.018975	777	331	-3.011446
773	33h	-4.415052	778	33m	-3.127130
774	33i	-4.972067	779	33n	-3.436488
775	33j	-4.816826	780	330	-3.994591

781	33p		-3.713055	786	33u		-3.401185
782	33q		-4.937042		33v		-1.248823
783	33r		-4.799076	788	33w		-2.424660
784	33s		-4.325091	789	33x		-3.419863
785	33t	The state of the s	-4.415052	790	33у	N H H	-3.412892
791	33z	H H H	-4.972067	796	34e	A PART OF THE PART	-3.704842

792	34a	0 0	-3.301119	797	34f	ÇI	-2.882619
						8	
						H N N	
						Ĭ	
793	34b) 	-0.625637	798	34g	, N=0	-4.279670
		N N N N N N N N N N N N N N N N N N N				H	
						, , , , , , , , , , , , , , , , , , ,	
794	34c	н—н	-2.872770	799	34h	◇ N°	-1.333442
			(I)				
		N H	$\mathcal{X} = \mathcal{X}$			N S	
795	34d		-3.110456	800	34i	н н	-2.966944
						I North	
K	0	N O					
801	34j	н	-1.827941	806	340	1 C	-3.663190
				1			
						N H	
		H				Н	
802	34k	o o	-1.248823	807	34p	ļ	-3.088192
						N H	
		N N				N S	

но	-2.424660	808	34q		-3.362113
				H H	
H N N N N N N N N N N N N N N N N N N N			·	N S	
Н					
	-3.419863	809	34r		-2.066932
H					
				N H	
				H .	
	-3.412892	810	34s		-3.784437
H				H H	
				N O	
N	-3.704842	816	34y		-2.535225
N N N				Type of the state	
				C	•
N/	-2.882619	817	34z		3.905382
N H				i i i i i i i i i i i i i i i i i i i	
H				N H	
H	-4.279670	818	35a	н	-3.960534
H N S					
н				, N	
		-3.419863 -3.412892 -3.704842 -2.882619	-3.419863 809 -3.412892 810 -3.704842 816 -2.882619 817	-3.419863 809 34r -3.412892 810 34s -3.704842 816 34y -2.882619 817 34z	-3.412892 810 34s -3.704842 816 34y -2.882619 817 34z

814	34w		-1.333442	819	35b	li li	-4.507489
						","	
		H N S					
01.5	0.4	н		020	25		
815	34x	***	-2.966944	820	35c	н	-4.116265
		1				N N N N N N N N N N N N N N N N N N N	
821	35d	, N=0	-3.663190	826	35i		-3.567000
		i I					
						7 7	
822	35e	.0	-3.0881 <mark>92</mark>	827	35j	P	-3.161491
	_						
		N H				No. 1	
823	35f	N=0	-3.362113	828	35k	-0	-4.421368
							•
		N O				The second secon	
						"	
824	35g		-2.066932	829	351		-2.968208
						, H	
		N N					
						н	

825	35h		-3.784437	830	35m		-4.225955
						N H	
		N O				н	
831	35r		-2.535225	836	35w		-4.963976
			-				
		N H				N H	
		H				. H	
832	35s	q	3.905382	837	35x		-3.308057
					"		
		N H	\bot				
	_	N S				H	
833	35t		-3.960534	838	35y		-4.896991
			3.30033 .			, J))
		, H					
	0	N S					1
1						C	h
834	35u	Н	-4.507489	839	35z	13	-3.797137
		N H				N H	
		T T				H N S	
835	35v	н	-4.116265				
		, H					
		N S					

06.3 Selection of best docked analogues for synthesis:

06.3.1 Selected 20 best docked analogues for synthesis:

Table no. 6.2 20 best docked analogues for synthesis

Comp.code	Structure			Structure	Dock
		score	code		score
HDB-1			RLS-4	N S	-2.537
HDB-2			RLS-5		-1.820
HDB-3		-3.331	RLS-6	H _F C	-3.008
HDB-4			RLS-7	C CH	-2.287
HDB-5	H ₂ C N CH ₄	-3.466	RLS-8	CH ₃	-3.055

HDB-6	он <u>»</u>	-4.135	RLS-9	0	-3.340
	H ₂ C H ₃ C H ₄ C			N CH ₃	
HDB-7	N S	-2.274	RLS-10		-2.649
RLS-1	H ₃ C O	-3.704	RLS-11	HPC O H CH4	-3.102
RLS-2	H,C O H	-2.958	RLS-12	C CH ₃	-3.156
RLS-3	CI H	1	RLS-13	CH ₃	-3.324
			MTX STD	MTHOTREXATE	-1.576

06.4 Docking interactions of active best docked analogues:

For checking binding interaction first open receptor in MDS followed by compound which saved as ligand dock file. From tool option click on merge molecule so that compound and receptor is merged together. From biopredicta tool edit this complex and select ligand and receptor structure afterward check its interaction.

06.4.1 Docking interaction of compounds with microbial DHFR on PDB code3FRE:

06.4.1.1 Docking interactions of HDB-2:






Fig. 6.9 HDB-2 VdW bonding


Fig. 6.10 2D HDB-2 Hydrogen bonding


06.4.1.2 Docking interactions of HDB-6:





06.4.1.3 Docking interactions images of RLS-10:





06.4.1.4 Docking interactions images of Trimethoprim:






Table no. 6.3 Docking interaction of compounds with microbial DHFR on PDB code3FRE

Comp.	Hydrogen	bonding	Hydropho	obic bon	ding	VdW bon	nding
HDB-2	SER49X	1.943	GLN19X LEU20X THR46X SER49X ILE50X	4.3 4.4 3.2	340 418 182 469	GLN19X LEU20X LEU28X THR46X SER49X ILE50X PHE92X	3.393 3.819 3.515 3.283 3.636
HDB-6	SER49X	1.657	GLN19X LEU20X LEU28X THR46X SER49X	4.9 4.9 4.8	937 900 898	GLN19X LEU20X LEU28X THR46X SER49X	3.020 3.255
10			ILE50X LEU54X	4.9	933 572	ILE50X LEU54X PHE92X	3.255 3.644 3.056
RLS-10	SER49X	2.589	LEU20X THR46X			LEU20X LEU28X THR46X SER49X ILE50X PHE92X	3.793
STD TMP			LEU20X LEU28X VAL31X THR46X SER49X ILE50X GLY93X	4.777 4.849 3.865 3.7 4.0	718 025	LEU20X LEU28X THR46X SER49X ILE50X PHE92X GLY93X	3.033 3.865 3.718 3.383 3.032


06.4.2 Docking interaction images of compounds with cancer cell DHFR on PDBcode 2W3M:


06.4.2.1 Docking interaction images of HDB-2:






06.4.2.2 Docking interaction images of HDB-6:






06.4.2.3 Docking interaction images of RLS-5:



06.4.2.4 Dockin<mark>g int</mark>eraction images of Methotrexate:






Table no. 6.4 Docking interaction of compounds with cancer cell DHFR on PDBcode 2W3M

Comp.	Hydrogenbonding	drophobicbonding		Charge interactions
HDB-2		LEU20X 4.340 THR46X 4.418 SER49X 3.182	GLN19X 3.426 LEU20X 3.393 LEU28X 3.819 VAL31X 3.353 THR46X 3.515 SER49X 3.407 ILE50X 3.636 PHE92X 3.936	
HDB-6	ASP145A2.442	GLY20A 2.347 LYS55A 4.232 THR56A 3.804 THR146A 4.651	ASN19A 3.497 GLY20A 3.569 LYS55A 3.018 THR56A 3.298 GLY117A 3.668 ASP145A 3.853 THR146A 3.366	ASP145A 4.057
RLS-5	IR146A1.836		1 ILE16A 3.794 GLY17A 3.126 ASP21A 3.656 LEU22A 3.846 LYS55A 3.851 THR56A 3.205 GLY116A 3.742 THR146A 3.503 ASP145A 3.106	CR
STD MTX	GLY20A- 2.495	GLY117A- 4.758 THR146A- 4.355 ARG137B- 4.728 LYS178B- 4.847	GLY20A - 3.390 GLY17A -3.293 ASN19A - 2.941 PHE34A- 3.398	LYS178B- 3.738

06.5 Discussion:


From the above molecular modeling and docking study compounds were selected on the basis of docking score, docking interactions and interaction distance in comparison with trimethoprime and methotrexate. Selected compounds have docking score less than standard compounds with same docking interactions and matching interaction distance with standard.



07. DESIGN OF SCHEME:

For the synthesis of 8,10 di methyl-12aryl -8,12 dihydro-7oxa-8,10diaza benzoanthracene 9,11 dione schemes were designed.

07.1 Reaction scheme-I:1,2



O 1,3 dicarbonyl compund

8,10 dimethyl-12 aryl -8,12 dihydro-7oxa 8,10 diazabenzoanthracene 9,11dione

O

07.2 Mechanism of Reaction scheme

The step involves aluminium chloride catalysed one pot synthesis of 8,10 dimethyl- 12aryl-8,12 dihydro-7 oxa-8,10 diabenzo anthracene 9,11 dione.


⁴.various aromatic aldehyde containing electron withdrawing group& electron donating group substitutes at ortho, para, meta shows equal ease of towards reaction.

Efficient one pot condensation of beta napthol, aldehyde, cyclic 1-3 dicarbonyl compound had been achieved with molecular iodine as a catalyst under microwave irradiation thus variety of tetra hydro benzo (a)xanthene11 one diabenzo(a)anthracene 9,11 dione.



08. SYNTHESIS OF COMPOUNDS:


08.1 Scheme



0 1,3 dicarbonyl compund

8,10 dimethyl-12 aryl -8,12 dihydro-7oxa 8,10 diazabenzoanthracene 9,11dione

 \mathbf{O}



08.1.1 General procedure for scheme-:

Step: General procedure for synthesis of 8,10 diaza benzoanthracene 9,11 dione analogues:

These compounds were synthesized by the reported cyclocondensation reaction between aldehyde, beta napthol and dimedone. The mixture of appropriate aldehyde (0.02 mol), beta napthol (0.02 mol), dimedone (0.03 mol), aluminium chloride (0.01 mol), were refluxed for 4-6 hours. The solid thus separated on cooling was filtered, washed with coldmethanol, dried and recrystallized from methanol.

1) 8,10 dimethyl-12chloro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene9,11dione (pvv-1):

A mixture of 2-chlorobenzaldehyde, beta napthol, dimedone,& alluminium chloride was taken in round bottom flask and refluxed for 4-6 hrs.

Melting point: 175°C, yield: 84.85%.

2) 8,10 dimethyl-12 benzo chloro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene9,11 dione (pvv-2):

A mixture 3 chloro benzaldehyde, beta napthol, dimedone, alluminium chloride was taken in round bottom flask and refluxed for 4-6 hrs.

Melting point: 187°C, yield: 82.87%.

3) 8,10 dimethyl-12 benzo chloro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-3):

A mixture of 4-chlorobenzaldehyde, beta napthol, dimedone, alluminium chloride was taken in round bottom flask and refluxed for 4-6 hrs.

Melting point: 149°C, yield: 83.77%.

4) 8,10 dimethyl-12 benzo nitro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-4): A mixture of 4-nitrobenzaldehyde, betanapthol, dimedone, alluminium chloride was taken in round bottom flask and refluxed for 4-6 hrs.

Melting point: 131°C, yield:

Melting point: 149°C, yield: 83.77%.

5) 8,10 dimethyl-12 benzo 3-nitro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-5):A mixture of 3-nitrobenzaldehyde, betanapthol, dimedone, aluminium chloride was taken in volumetric flask undergoes microbial irradiation

Reaction time: 1 h, Melting point: 208°C, yield: 85.23 %

6) 8,10 dimethyl-12 benzo para hydro -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-4):A mixture of p-hydro benzaldehyde, betanapthol, dimedone, aluminium chloride was taken in volumetric flask undergoes microbial irradiation reaction time: 1 h,

7) 8,10 dimethyl-12 salicylaldrhyde -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-4):A mixture of salicylaldehyde , betanapthol, dimedone,aluminium chloride was taken in volumetric flask undergoes microbial irradiation reaction time :1 h,

Reaction time: 2 h, Melting point: 202°C, yield: 73.20 %

8) 8,10 dimethyl-12 anise aldehyde -8,12 dihydro-7 oxa-8,10 diaza benzo anthracene 9,11 dione (pvv-4):A mixture of anise aldehyde, betanapthol, dimedone, aluminium chloride was taken in volumetric flask undergoes microbial irradiation reaction time: 1 h,

Reaction time: 2 h, Melting point: 210°C, yield: 78.40 %




Table no. 08.1 Merck index

Merck Index	ChemicalName (Mol. Form.)	Mol.Wt.	ensity g/ml	Physical Constant		Solubility	Caution
No.				MP °C	BP °C		
1481	Acetyl acetone (C ₅ H ₈ O ₂)	100.12	0.98	-23	14 0	Soluble in water, alcohol, ether, chloroform, hot benzene	-

	1	100.01				~	1
335	Aluminium chloride (AlCl ₃)	133.34	-	-	-	Soluble in organic solvent	Anhydrous form is strong irritant
1057	Benzaldehyde (C ₇ H ₆ O)	106.12	1.04	-56.5	17 9	Miscible with alcohol, ether, oils	Narcotic in high conc. May cause contact dermatitis
2214	4-Chloro Benzaldehyde (C ₇ H ₅ ClO)	140.56	1.119	46	21 4	Alcohol, Ether	-
3285	Dimethylsulfo xide	78.13	1.1	18.5 5	18 9		Rapidly absorb through skin
3792	Ethyl acetate (C ₄ H ₈ O ₂)	88.10	0.902	-83	77	Miscible with alcohol, acetone, chloroform	Irritating to eyes, noseand throat
4801	Hydrochloric acid (HCl)	36.5	1.05	-			Corrosive burns due to inhalation of acid fumes.
4856	4-Hydroxy benzaldehyde (C ₇ H ₆ O ₂)	122.12	·	-	-	Alcohol, Ether, acetone	31
5984	Methanol (CH ₄ O)	32.04	0.79	-97.8	64	Miscible with water, ethanol, ether, benzene	Irritation of eyes, skin and mucous membrane.
6110	Methyl iodide (CH ₃ I)	141.94	2.28	-66.5	42. 5	ether	Overexposu re cause nausea, vomiting, vertigo,ataxia
6684	<i>p-</i> Nitrobenzaldeh yde (C7H5NO2)	151.12	-	106- 107	-	Soluble in alcohol, benzene	-
	3- Nitrobenzaldeh	151.12	-	58	16	Alcohol, Ether,	-

l t	yde (C7H5NO2)				4	Chloroform	
8060	Pyridine (C ₅ H ₅ N)	79.10	0.982	-41.6	5.2	alcohol, ether, petether, oils	Headache, nervousness , dizziness and insomnia
9443	Thiourea (CH ₄ N ₂ S)	76.12		176- 178		water, alcohol andether	Chronic administration in rats has resulted in hepatic tumors
8613	Sodium ethoxide (C ₂ H ₅ NaO)	68.05		260		Soluble in water and alcohol	-



09. IDENTIFICATION AND CHARACTERIZATION:

09. Identification and Characterization¹⁻⁴

The Identification and Characterization of the compounds was carried out by thefollowing methods.

- 1) Melting point
- 2) Thin layer chromatography
- 3) Infrared spectroscopy
- 4) Nuclear magnetic resonance spectroscopy
- 5) Mass spectroscopy

09.1 Melting Point¹

The melting points of the organic compounds were determined by open capillary tube method. Melting point is the valuable criteria for an organic compound as pure crystal is having definite and sharp melting point. Determining the melting point is a simple and fast method used in many diverse areas of chemistry to obtain a first impression of the purity of a substance. This is because even small quantities of impurities change the melting point, or at least clearly enlarge its melting range. Melting points were determined by using Veego electronic (VMP-D) apparatus.

09.2 Thin Layer Chromatography²

Chromatography is an important technique to identify the formation of the new compounds and also to determine the purity of the compounds. The Rf value is the characteristics for each compounds. Thin layer chromatography is performed to monitor the completion of reaction. TLC is a method in which a thin layer of some inert material is used as a substrate. A layer of oxides is made from slurry of powder in a suitable inert solvent. In the present work, silica gel G (Loba) is used as coating material. The solvent used for development of TLC was benzene: ethyl acetate in various concentrations.

09.3 Infrared Spectroscopy^{3,4}

The infrared radiation spectroscopy is concerned about the absorption of infrared radiation by a molecule and exhibits characteristics absorption spectra. The most useful

range for analytical purpose lies between 4000 and 400 cm⁻¹. After absorption of IR radiations by a chemical substance, molecules of substance vibrate at many rates of vibrations giving rise to closely packed absorption bands, commonly known as IR absorption spectrum. Although the IR spectrum is characteristic of the entire molecule, it is true that certain groups of atoms give rise to bands at or near the same frequency regardless of structure of the rest of the molecule. It is the persistence of these characteristic bands that permits the chemist to obtain useful structural information by simple inspection and reference to generalized charts of characteristic group frequencies. Different bonds (C-C, C-O, C=O, O-H, N-H etc) have different vibrational frequencies, and we can detect the presence of these bands in an organic molecule by identifying this characteristic frequency as an absorption band in the infrared spectrum.

The IR spectra of compoundswere recorded on a JASCO FT-IR 4100spectrometer.

09.4 Nuclear magnetic Resonance Spectroscopy^{3,4}

Nuclear magnetic resonance (NMR) is a form of absorption spectroscopy. It is concerned with the absorption of certain energy by spinning nuclei in a magnetic field when irradiated by certain energy radiation perpendicular to it. NMR is concerned with the magnetic properties of certain atomic nuclei, notably the nucleus of hydrogen atom the proton. Studying a molecule by NMR spectroscopy enables us to record differences in the magnetic properties of the various magnetic nuclei present, and to deduce in large measure what the positions of these nuclei are within the molecule.

The ¹H NMR spectra were obtained on a BRUKER AVANCEV II 400 NMR spectrometer in DMSO as solvent and TMS as internal standard, chemical shifts are given in ppm.

09.5 Mass spectroscopy^{3,4}

Mass spectrometry is an analytical tool used for measuring the molecular mass of a sample. Mass spectra are obtained after ionisation of samples by different ionization techniques. Molecular mass of the compound is determined by mass to charge (m/z) ratio.

The mass spectra were obtained on WATERS Q-TOF MICROMASS (LC-MS).

09.6 Physicochemical Characteristic of Compounds

Table no. 09.1 Physicochemical Characteristic of Compounds

olecular Code	Molecular Structure	Aolecular Formula	Mol. Weig -ht	Ielting Point (⁰ C)	Yield(%)	R _f Value
HDB-1				(C)		
		C ₁₄ H ₁₆ N ₂ O ₂	244	175	84.85	0.377
HDB-2		C ₁₄ H ₁₆ N ₂ OS	260	187	82.87	0.2
HDB-3						
прв-э		C ₁₃ H ₁₃ N ₂ OSCl	280	149	83.77	0.370
HDB-4		C ₁₃ H ₁₃ N ₃ O ₃ S	291	131	69.67	0.3
HDB-5		C ₁₄ H ₁₈ N ₂ OS	262	109	77.33	0.339
HDB-6		C ₁₅ H ₂₀ N ₂ OS	276	202	85.23	0.392
HDB-7		C ₁₄ H ₁₇ N ₃ OS	294	161	73.20	0.26
RLS-1		C ₁₂ H ₉ N ₃ OS	243	257	48.67	0.65
RLS-2						

		C ₁₂ H ₉ N ₃ O ₂ S	259	275	57.45	0.45
RLS-3	GI H	C ₁₁ H ₆ N ₃ OSCl	264	237	45.35	0.46
RLS-4	D HO	C ₁₁ H ₇ N ₃ O ₂ S	245	249	57.35	0.28
RLS-5		C ₁₁ H ₆ N ₄ O ₃ S	274	217	35.97	0.32
RLS-6	CH CH	C13H11N3O3	241	162	75.59*	0.24
RLS-7	CH ₀	C ₁₃ H ₁₁ N ₃ O ₂	257	215	69.45	0.78

RLS-8	CH ₃	C1 ₂ H ₈ N ₃ O ₂ Cl	261	169	69.45	0.1
RLS-9	N CH ₃	C12H9N3O3	243	141-142	53.47	0.28
RLS-10	CH,	C ₁₂ H ₈ N ₄ O ₄	272	256	45.45	0.40
RLS-11	H _C C H CH ₀	C ₁₃ H ₁₁ N ₃ O ₂ S	273	245	58.45	0.36
RLS-12	O CH ₃	C ₁₂ H ₈ N ₃ OCl	277	249	64.39	0.23

RLS-13	O CH ₃	C ₁₂ H ₈ N ₄ O ₃ S	288	223	34.56	0.39



Table no. 09.2 Elemental Analysis of Title Compounds

	Elements						
Compound	C	Н	O	N	S	Cl	
HDB-1	69.83	6.60	13.10	11.47			
HDB-2	64.58	6.19	6.17	10.86	12.32		
HDB-3	55.61	4.67	5.70	9.98	11.42	12.63	


HDB-4	53.60	4.50	16.48	14.42	11.01	
HDB-5	64.09	6.91	6.10	10.68	12.22	
HDB-6	65.18	7.29	5.79	10.14	11.60	
HDB-7	56.65	5.77	5.39	9.44	10.80	11.94
RLS-1	59.24	3.73	6.58	17.27	13.18	
RLS-2	55.59	3.50	12.34	16.21	12.37	
RLS-3	50.10	2.29	6.07	15.93	12.16	13.44
RLS-4	53.83	2.88	13.05	17.13	13.07	
RLS-5	48.17	2.21	17.50	20.43	11.69	
RLS-6	64.72	4.60	13.26	17.42		
RLS-7	60.70	4.31	18.66	16.33	1	/
RLS-8	55.08	3.08	12.23	16.06		13.55
RLS-9	59.29	3.73	19.73	17.28		
RLS-10	52.95	2.96	23.51	20.58		
RLS-11	57.13	4.06	11.71	15.37	11.73	
RLS-12	51.90	2.90	5.76	15.13	11.55	12.77
RLS-13	50	2.80	16.65	19.43	11.12	

$09.8 \ IR \ data \ of \ title \ compounds:$

Table no. 09.3 IR data of title compounds:

Compound	IR value (cm ⁻¹)			
HDB-1	3296.71 (NH stretch), 2911.02 (CH stretch),1738.51 (C=O), 1702.84(C=O Amide), 912 (C-N).			
HDB-2	3203.18 (NH stretch), 2828.1 (CH stretch), 1733.69 (C=O), 910 (C-N)			
HDB-3	3301.54 (NH stretch), 3046.98 (CH stretch), 1692.23 (C=O), 821.527 (C-Cl), 916 (C-N).			
HDB-5	3249.47 (NH stretch), 2926.45 (CH stretch), 3030.59 (CH stretchSP2), 1806.51 (C=O), 962(C-N).			
HDB-6	3291.89 (NH stretch), 3020.94 (CH stretch SP2), 2921.63(CH stretch), 1697.05 (C=O), 957 (C-N).			
HDB-7	3650 (NH stretch), 2832 (CH stretch), 2921.63(CH stretch), 1697.05 (C=O), 957 (C-N).			
RLS-1	3187.76 (NH stretch), 3099.05(CH stretch SP2), 1692(C=O), 2228.13 (CN), 611 (C-O).			
RLS-2	3187.76 (NH stretch), 3067.23 (CH stretch SP2) 2942.84 (CH stretch),1707.66 (C=O), 2234.13(CN).			
RLS-3	3208 (NH stretch), 3093.26 (CH stretch SP2), 754.031 (C-Cl), 1707.66 (C=O), 2338.27 (CN), 903 (C-N).			
RLS-4	3614.91 (OH stretch), 3307.32 (NH stretch), 2958.27 (CH stretch), 1785.76 (C=O), 2228.34 (CN), 837(C-O).			

RLS-7	3197.4 (NH stretch), 2978.52 CH stretch), 1697.05(C=O), 2228.349 (CN), 931 (C-N),
RLS-9	3609.13 (OH stretch), 3312.14 (NH stretch), 2958.27 (CH stretch), 2228.34 (CN), 1785.76 (C=O).
RLS-10	3359.39 (NH stretch), 3088.44 (CH stretch SP2), 2989.12 (CH stretch), 2228.34 (CN), 1728.87 (C=O).
RLS-12	3181.97 (NH stretch), 3030.59 (CH stretch SP2), 2900.41 (CH stretch), 2369.12 (CN), 1692.23 (C=O), 754.031 (C-Cl).



IR spectra of respected compounds have shown in following figures.




Fig 9.1 IR spectra of 5-acetyl-6-methyl-4-p-tolyl 1,2,3,4-tetrahydropyrimidin-2-one: (HDB-1)




Fig 9.2 IR spectra of 5-acetyl-6-methyl -4-p-tolyl-2-thioxo -1,2,3,4-tetrahydropyrimidine: (HDB-2)




Fig 9.3 IR spectra of 5-acetyl-6-methyl-4-p-chlorophenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine: (HDB-3)








Fig. 9.4 IR spectra of 5-acetyl-6-methyl-2-methylthio-4-phenyl-1,2,3,4-tetrahydropyrimidine: (HDB-5)












Fig 9.9 IR spectra of 5-carbonitrile-4-oxo-2-thioxo-6-(p-chlorophenyl)-1,2,3,4-tetrahydropyrimidine:(RLS-3)




Fig 9.10 IR spectra of 5-carbonitrile-4-oxo-2-thioxo-6-(p-hydroxyphenyl)-1,2,3,4-tetrahydropyrimidine:(RLS-4)






Fig 9.11 IR spectra of 1,2,3,6-tetrahydro-1-methyl-2,6-dioxo-4-pmethoxyphenylpyrimidine-5-carb- onitrile: (RLS-7)



9.12 IR 1,2,3,6-tetrahydro-1-methyl-2,6-dioxo-4-p-Fig spectra of hydroxyphenylpyrimidine-5-carbonitrile: (RLS-9)



nitrophenylpyrimidine-5-carbonitrile: (RLS-10)




Fig 9.14 IR spectra of 1,2,3,6-tetrahydro-4-(4-chlorophenyl)1-methyl-6-oxo-2-dioxopyrimidine-5-carbonitrile: (RLS-12)

09.9 ¹H NMR data of respected compounds: Table no. 09.4 ¹H NMR data of title compounds:

Compound	¹ H NMR
HDB-6	7.8-(d, 4H, CH benzene), 6.7-(s, 2H, methine), 1.1-(s, 6H, methyl), 2.5-(s, 2H, N-H), 1.2(s, 3H, methyl).
RLS-7	8.25-(d, 4H, benzene),7.22-(s, 1H, NH), 3.86-(s, 3H, methyl), 2.50(s, 3H, methyl).
RLS-12	7.8-(d, 4H, Benzene), 3.36-(s, 3H, methyl), 3.19-(s, 1H, N-H).

¹HNMR spectra of respected compounds are shown in following figure.





Fig 9.15 ¹HNMR spectra of 5-acetyl-6-methyl-2-methylthio-4-tolyl-1,2,3,4-tetrahydropyrimidine: (HDB-6)



methoxyphenylpyrimidine-5-carbonitrile: (RLS-7)





Fig 9.17 1 HNMR spectra of 1,2,3,6-tetrahydro-4-(4-chlorophenyl)1-methyl-6oxo-2-dioxopyrimidine-5-carbonitrile: (RLS-12)

09.10 Mass Spectroscopy data of tital compounds:

Table no. 09.5Mass Spectroscopy data of tital compounds:

Compound	m/z ratio value
HDB-6	276.2 (100%) , 277.2(18.0%) (M+1 peak)

Mass spectra of tital compound have shown in following figure.





10. BIOLOGICAL SCREENING

10.2 Anti-microbial Activity: 5-11

An anti-microbial is substance that kills or inhibits their growth. Biological evaluation involves testing of the microbial susceptibility to chemotherapeutic agents. Determination of antimicrobial effectiveness against pathogens is essential for proper therapy. Antimicrobial susceptibility may be reported qualitatively, as sensitive, intermediate or resistant or quantitatively in terms of the concentration of agent which inhibits the growth of the organism. The organism being 'sensitive' means that the organism is inhibited by the antimicrobial agent at clinically attainable concentration; 'resistant' means that the growth of the organism is not inhibited. The basic principle of microbial assay lies in the comparison of the inhibition of the growth of bacteria by measured concentration of antibiotic to be investigated with that produced by known concentration of the standard preparation of the antibiotic having a known activity. The idea of the effectiveness of a chemotherapeutic on of agent against pathogen can obtained from the Minimum Inhibitory Concentration (MIC). Minimum inhibitory concentration is defined as the lowest concentration of antimicrobial agent that can inhibit the visible growth of microorganism after overnight incubation. MIC is important in diagnostic laboratories to confirm resistance of the microorganism to an antimicrobial agent and also to monitor the activity of new antimicrobial agents.

10.2.1 Methods:

The following two are the methods:

10.2.1. 1. Diffusion method:

A Petri plate containing an agar medium is inoculated uniformly over its entire surface with standardized amount of the test organism. Filter paper disks impregnated with known concentration of chemotherapeutic agents are placed on the solidified agar

JCR

surface. During incubation, chemotherapeutic agents diffuse from the disks into the agar. The agent diffuses from the disk, lower its concentration. If the chemotherapeutic agent is effective, a zone of inhibition forms around the disk after a standardized incubation. A more advanced diffusion method, the E test, enables a lab technician to estimate the minimum inhibitory concentration. A plastic coated strips gradient of antibiotic concentration and MIC can be read from a scale printed on the strip.

10.2.1. 2. Broth Dilution method:

Broth dilution is useful in determination of MIC and minimum bactericidal concentration (MBC) of an antimicrobial activity.MBC is lowest concentration of the antimicrobial agents that kills the test organism. The MIC is determined by making a sequence of decreasing concentration of the drug in a broth, which is then inoculated with the test bacteria. After incubation the turbidity may be read visually or by measuring the percentage transmittance or absorbance at 600 nm against a blank.

The tube dilution test is the standard method for determining levels of microbial resistance to an antimicrobial agent. Serial dilutions of the test agent are made in a liquid microbial growth medium which is inoculated with a standardized number of organisms and incubated for a prescribed time. The lowest concentration (highest dilution) of test agent preventing appearance of turbidity (growth) is considered to be the minimum inhibitory concentration.

10.2.2 Material and Methods:

10.2.2.1 Requirements:

Apparatus

Test tubes, Test tube stand, Bunsen burner, Culture media, Measuring cylinder, Inoculating loop, 1 mL and 5 mL Glass syringe.

Equipments

UV-Vis Spectrophotometer (Jasco)

Laminar airflow (The Popular Science Apparatus, India) Autoclave (Dolphin)

BOD Incubator (Labline)

Chemicals

Beef extract (Loba Chemie Pvt.Ltd.), Peptone (Loba Chemie Pvt.Ltd.), Sodium chloride(Qualigens), Distilled water, Dettol and Dimethylformamide ((Merck).

Nutrient Broth

Nutrient broth is used to find growth of organism in a test tube and screw-caped culture tube. Test tube broth culture is advantageous in the sense that it can be easily handled. Microbes exist in the fluid independently or in a cluster form with minimum contamination.

Sr.No.	Ingredients	Quantity
1.	Beef extract	10.0 gm
2.	Peptone	10.0 gm
3.	Sodium chloride	5.0 gm
4.	Distilled water	q.s. up to 1000 mL

Table no.10.4 Composition of nutrient broth

10.2.2.2 Preparation of Nutrient Broth:

Put the weighted amount of beef extract, sodium chloride and peptone in 500 mL of distilled water. Heat the mixture and agitate with glass rod to dissolve the ingredients. Add distilled water to make the final volume. Adjust the pH of the medium to 7.2-7.4 by adding acid or alkali.

10.2.2.3 Sterilization of Equipments:

The operating procedures of an autoclave are as follows:

- 1) Autoclave was filled and heated till steam started building up.
- 2) Items to be sterilized were placed in the chamber.

- 3) The autoclave door was then closed and locked.
- 4) When temperature reached 100°C, operating valve was closed.
- 5) The jacket pressure was then checked.
 - The sterilization time was measured from the moment temperature reached 121°Crather than 6) 15 lb pressure, sterilized it for 15 min.
 - 7) After 15-20 min, the steam supply valve was closed and waits till the pressure falls tozero.
- 8) The autoclave door was unlocked and opened.
- 9) Autoclaved items were removed from the chamber.

10.2.2.4 Preparation of Solutions:

Stock Solution of Test Compounds

The test compounds (5 mg) were dissolved in 1 mL of DMF and volume was adjusted upto 2 mL with DMF to produce a concentration of 2500 µg/mL.

Preparation of Standard Antibiotic Solution

ofloxacin was also prepared in DMF to obtain a concentration of 500 μg/ml to 3.9 μg/ml.

Preparation of Saline Solution: 0.9 gm sodium chloride dissolved in 100 mL distilledwater.

Cultures

All pathogenic strains of bacteria were procured from National Collection of Industrial Microorganism (NCIM) Pune, India. The microorganisms, which were maintained by sub culturing, were used at regular intervals in nutrient agar medium.

Sr.No.	ldard	Micro-organism	M CodeNo.		
		Gram + Ve			
1	Stap	hylococcus aureus	2079		

	Gram – Ve	
3	Escherichia coli	2089

Table no. 10.5 Microorganisms used for antibacterial activity

0.2.2.5 Preparation of Inoculums:

Bacterial Suspension:

Recently grown stock culture of each of the test organism was used to prepare subculture on the surface of a suitable volume of nutrient broth. The bacterial cultures were incubated at 30 to 35°C for 18 to 24 h.

Bacterial Saline Solution:

Bacterial suspension of 1 mL was added in 99 mL of sterile saline solution to prepare bacterial saline solution.

Control Parameters:

Media Control: Sterilized medium was kept for growth (48 h) so as to assure the sterility of the medium. If this control shows growth of any type, then the media were discarded.

Culture Control: The culture of the organism was inoculated in sterilized medium. If no growth was observed, then the culture was considered to be faulty. The fresh culture was prepared.

0.2.2.6 Precautions:

- 1) Add test solution and standard solution in the alternate manner in test tube.
- 2) Remaining microbial culture is to be discarded after adding disinfectant.
 - 3) Dissolve an accurate quantity of the standard preparation of the antibiotic in suitable solvent. This stock solution should be stored in refrigerator and used within the period as specified in the pharmacopoeia.
- 4) Remember to the mix the contents of each tube well between.

0.2.2.7 Procedure: 12, 13

- 1) Into test tube rack, placed a one set of 9 sterile 13×100 mm test tubes labeled 1 through 9. Labeled one rack set I control (blank), gram positive Set II- *Staphylococcus aureus*, gram negative Set III-*Escherichia coli*.
- 2) 0.6 ml of DMF in labeled 1 and 0.5 ml of DMF in labeled 2 through labeled 9 in Set I- III was added by using a sterile 1 ml glass syringe.
- 3) 0.4 ml test compound solution in labeled 1 test tube was added by using a sterile 1 ml glass syringe and then mixed it.
- 4) Using a sterile 1 ml glass syringe, test compound solution 0.5 ml from tube 1 to tube 2 was transferred. It was mixed well and then transferred 0.5 ml from tube 2 to tube 3. This procedure was continued through tube 9. Then 0.5 ml from test tube 9 was discarded.

Table no. 10.6 Test compounds serial dilution-broth medium setup

	Test Tube Number										
Additions	1	2	3	4	5	6	7	8	9	Media	Cultu
(mL) to:										Contr-ol	-re
	~								6	14.	Contr
A. S.	3								3) "	-ol
DMF	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Compound	0.4	Serial	Diluti	ons		l	1			-	-
Medium	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.4	4.5	4.4
Test	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-	0.1
Culture											
Compound	1000	500	250	125	62.5	31.2	15.6	7.8	3.9	-	-
(μg/mL)						5	2	1			

- 5) 4.4 ml of nutrient broth in labeled 1 to labeled 9 in set I-III was added by using asterile 5 ml glass syringe.
- 6) 0.1 ml of the 1:1000 dilution of the microorganism in set II and III was added by using a sterile 1 ml glass syringe.
- 7) At the same time two control tubes were prepared.
- a) One containing the inoculated media control.
- b) One containing the inoculated culture media control.
- 8) Incubated all sets of tube for 42-48 h at 37°C.
 - 9) The growth of test organism was measured by determining the extinction at 600 nm of each of the solution in the tube against the blank (Set I).



10.2.3 Results of anti-microbial activity:

Sr.No.	mpoundcode	Anti-microbial activity (MIC) microgram			
		Staphylococcus aureus	Escherichia coli		
1	HDB-1	62.5	62.5		
2	HDB-2	7.81	7.81		
3	HDB-3	62.5	125		
4	HDB-4	31.25	62.5		
5	HDB-5	62.5	62.5		
6	HDB-6	7.81	15.31		
7	HDB-7	62.5	62.5		
8	RLS-1	125	250		
9	RLS-2	125	250		
10	RLS-3	62.5	125		
11	RLS-4	125	125		
12	RLS-5	62.5	62.52		
13	RLS-6	15.62	62.5		
14	RLS-7	31.25	62.5		
15	RLS-8	31.25	62.5		
16	RLS-9	62.5	125		
17	RLS-10	15.62	15.62		

18	RLS-11	125	250
19	RLS-12	31.25	62.5
20	RLS-13	31.25	62.5
STD	TMP	15.62	31.25

Table no. 10.7 Results of anti-microbial activity:

10.3 In-vitro anti-cancer activity:



Sr.No.	Compound	GI ₅₀ (µMol)	
	Code	σ150 (μ101)	
1)	pvv-1		
2	pvv-2		
3	pvv-3		
4	pvv-4		
5	pvv-5		
6	pvv-6		
7	pvv-7		
8	pvv-8		
9	pvv-9		

Table no. 10.8 Results of in-vitro anti-cancer activity:

Discussion:

Synthesized 10 analogues were subjected for , anti-microbial activity and in-vitro anti-cancer activity. .

In in-vitro anticancer activity any potent analogues was not found but analogues.



11. DISCUSSION

11.1 Molecular Docking:

Initially, molecular docking of 1,2,3,4-tetrahydro and 1,2,3,6-tetrahydro pyrimidine analogues shown good docking score when they were docked in DHFR Receptors using PDB 2W3M and 3FRE Docking score were ranging from -1.20 to -6.83. On the basis of docking study, 20 analogues out of 900 were selected for synthesis. Analogue HDB-2, HDB-6, HDB-7, RLS-5, RLS-6, RLS-10 are best docked analogues. Interactions of these analogues with DHFR receptor shown in **fig. No. 6.7 to 6.42**

11.2 Synthetic Work:

Here in, we have reported a simple method for the synthesis of 1,2,3,4-tetrahydro pyrimidine and 1,2,3,6-tetrahydropyrimidine analogues. The reaction between substituted aldehyde, urea/thiourea and acetyl acetone in acidic condition yielded corresponding 1,2,3,4-tetrahydro pyrimidine which on reaction with methyl iodide and pyridine gives final substituted 1,2,3,4-tetrahydropyrimidine For the synthesis of 1,2,3,6-tetrahydropyrimidine analogues substituted aldehyde, substituted urea/thiourea and ethylogyanoacetate in sodium ethoxide is stirred for 48 hours. In this at first acyliminium ion formed which subsequently cyclize to the Biginelli dihydropyrimidines. structures of the synthesized compounds were characterized by melting point, TLC, IR spectroscopy, NMR spectroscopy and Mass spectroscopy.

11.3 Identification and Characterization:

Table 9.3 showing IR data of the intermediate and final compounds. The IR spectrum of compound showed an absorption band at 3240-3280 cm⁻¹ due to N-H stretch, 2996-3150 cm⁻¹ due to C-H aromatic stretch. (C=o) was observed at 1690- 1850cm⁻¹.

In **Table 9.4** the ¹H NMR data of the synthesized compounds have been mentioned. The ¹H NMR spectra of compound HDB-6 showed dublet at 7.8-(d, 4H, CH benzene), 6.7-(s, 2H, methine), 1.1-(s, 6H, methyl), 2.5-(s, 2H, N-H), 1.2(s, 3H, methyl); compound RLS-7 showed 8.25-(d, 4H, benzene), 7.22-(s, 1H, NH), 3.86-(s, 3H, methyl), 2.50(s, 3H, methyl) and compound RLS-12 shows 7.8-(d, 4H, Benzene), 3.36-(s, 3H, methyl), 3.19-(s, 1H, N-H).

Table 9.5 showing Mass spectroscopy data of the compound HDB-6 having m/z ratio at 276.2 (100%), 277.2(18.0%). Chromatogram is performed by using benzene:ethyl acetate in various proportion.

11.4 Biological activity:

11.4.1 Dihydrofolatereductase enzyme assay:

The DHFR enzyme assay was performed on DHFR enzyme assay kit on microplate spectrophotometer and results are shown in table no. 10.3 results of % Inhibition of DHFR Enzyme, reveals that the compounds **HDB-2, HDB-3, RLS-5, RLS-6, RLS-7** shows better % DHFR enzyme inhibition than standard methotrexate.

11.4.2 Antimicrobial activity:

Antimicrobial activity of title compounds was performed by broth dilution method in the drug concentration range 3.90 to 1000 ppm against E. coli and S. aureus. The results of anti-microbial activity are shown as minimum inhibitory concentration (MIC). Compounds **HDB-2**, **HDB-6**, **RLS-6**, **RLS-10** shows better anti-microbial activity than standard trimethoprim which is shown in table no.10.7 result of antimicrobial activity.

11.4.3 Anticancer Activity:

The *in-vitro* anticancer activity was performed by **Sulforhodamine B**(**SRB**) assay and results shown in table no. 10.8 results of in-vitro anti-cancer activity. *In-vitro* anticancer screening reveals that the compounds **HDB-1**, **HDB-2**, **HDB-6**, **HDB-7** shows mild anticancer activity.


12. CONCLUSION:

- 1. The molecular docking was used to prioritized the Anthracene analogues astopoisomerase ii inhibitors for synthesis.
- 2. The 1,2,3,4-tetrahydropyrimidine and 1,2,3,6-tetrahydropyrimidine analogueswere synthesized according to scheme.
- 3. Structures of title compounds were confirmed by IR, ¹HNMR & Mass spectra.
- 4. Compounds 5-Acetyl-6-methyl-4-p-tolyl 1,2,3,4-tetrahydropyrimidin-2-one (HDB-1); 5-Acetyl-6-methyl -4-p-tolyl-2-thioxo -1,2,3,4-tetrahydropyrimidine (HDB-2); 5-Carbonitrile-4-oxo-2-thioxo-6-(3-nitrophenyl)-1,2,3,4-tetrahydropyri- midine (RLS-5); 1,2,3,6-Tetrahydro-1-methyl-2,6-dioxo-4-p-tolypyrimidine-5-carbonitrile (RLS-6); 1,2,3,6-Tetrahydro-1-methyl-2,6-dioxo-4-p methoxyphenylpyrimidine-5-carbonitrile (RLS-7) shows potent DHFR Enzyme inhibition than standard Methotrexate.
- 5. Compound 5-Acetyl-6-methyl -4-p-tolyl-2-thioxo -1,2,3,4-tetrahydropyrimidine (HDB-2); 5-Acetyl-6-methyl-2-methylthio-4-tolyl-1,2,3,4-tetrahydropyrimidine (HDB-6); 1,2,3,6-Tetrahydro-1-methyl-2,6-dioxo-4-p-tolypyrimidine-5-carbon-itrile (RLS-6); 1,2,3,6-Tetrahydro-1-methyl-2,6-dioxo-4-p-nitrophenylpyrimidine-5-carbon-itrile (RLS-10) shows better anti-microbial activity on *S.aureus and E.coli* in comparison with standard Trimethoprime.

- 6. Compounds 5-Acetyl-6-methyl-4-p-tolyl 1,2,3,4-tetrahydropyrimidin-2-one (HDB-1); 5-Acetyl-6-methyl -4-p-tolyl-2-thioxo -1,2,3,4-tetrahydropyrimidine (HDB-2); 5-Acetyl-6-methyl-2-methylthio-4-tolyl-1,2,3,4-tetrahydropyrimidine (HDB-6); 5-Acetyl-6-methyl-2-methylthio-4-(p-chlorophenyl)-1,2,3,4-tetrahydropyrim- idine (HDB-7) shows mild *in-vitro* anti-cancer activity on MCF7 cell line in comparison with standard MTX.
- 7. Thus from this study it is concluded that molecular modeling can become a basic tool for anti-microbial and anti-cancer drugs research so that active molecules can be designed.

13. FUTURE SCOPE:

- 1. After the completion of literature survey it was observed that Dihydro Folate Reductase Enzyme receptor literally needs a detail studies in the era of their role in anti-microbial and anti-cancer as there are many anti-microbial and anticancer agents who has been targeted to DHFR.
- 2. With the help of docking score, docking interactions and results of anti-microbial screening on S.aureus, E.coli and anticancer screening on breast cancer (MCF-7) cell line, it was observed and concluded that when we will place hydrogen bond donor at 1st position, hydrogen bond acceptor at 4th position and longer aliphatic chain at 5 thand 6th position of pyrimidine skeleton; it will generate more potent analogues.



14. REFERENCES:

- 1. Tortora, Funke, Case, "Microbiology An Introduction", Eighth Edition, PearsonEducation, 439-448, (2005).
- 2. http://www.wikipedia.com
- 3. BariS.B., Mahajan B.M. and Surana S.J., Resistance to antibiotics: A challenge inchemotherapy, *Indian Journal of Pharmaceutical. Education and Research*, 42(1), 3-11, (2008).
- 4. Minfo.cancerresearchuk.org/cancerstats (WHO).
- 5. Hardman, Mibird, Gilman, Goodman & Gilman's The pharmacological basis of the rapeutics, 10th edition, 1381-1388, (2001).
- 6. www.els.net, Nature Publishing Group.
- 7. Croce C.M.. "Oncogenes and cancer". N. Engl. J. Med .358 (5) 502–11, 2008.
- 8. Knudson A.G. "Two genetic hits (more or less) to cancer". Nat. Rev. Cancer 1 (2) 157–62, (2001).
- 9. info.cancerresearchuk.org/breast cancer (WHO).
- 10. www.wikipedia.com
- 11. Chen MJ, Shimada T, Moulton AD, Harrison M, Nienhuis AW "Intronless human dihydrofolate reductase genes are derived from processed RNA molecules". *Proc. Natl. Acad. Sci. U.S.A.* 79 (23): 7435–9. doi:10.1073/pnas.79.23.7435. PMC 347354. PMID 6961421, (December 1982).
- 12. Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J, Nienhuis AW. "The functional human dihydrofolate reductase gene". *J. Biol. Chem.* 259 (6): 3933–43. PMID 6323448, (March 1984).
- 13. Funanage VL, Myoda TT, Moses PA, Cowell HR (October 1984). "Assignment of the human dihydrofolate reductase gene to the q11 q22 region of chromosome 5". Mol. Cell. Biol. 4 (10): 2010–6. PMC 369017. PMID 6504041.
- 14. Smith SL, Patrick P, Stone D, Phillips AW, Burchall JJ. "Porcine liver dihydrofolate reductase. Purification, properties, and amino acid sequence". *J. Biol. Chem.* 254 (22):11475–84. PMID 500653, (November 1979).
- 15. Schnell JR, Dyson HJ, Wright PE. "Structure, dynamics, and catalytic function of dihydrofolate reductase.". *Annual Review of Biophysics and Biomolecular Structure* 33 (1): 119–40. doi:10.1146/annurev.biophys.33.110502.133613. PMID 15139807, (June2004).
- 16. Urlaub G, Chasin LA. "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity". *Proc. Natl. Acad. Sci. U.S.A.* 77 (7): 4216–20. doi:10.1073/pnas.77.7.4216. PMC 349802. PMID 6933469, (July 1980)
- 17. Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. "Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways". *Journal of Biological Chemistry* 284 (41): 28128–36. doi:10.1074/jbc.M109.041483. PMC 2788863. PMID 19666465, (2009).
- 18. Li R, Sirawaraporn R, Chitnumsub P, et al.. "Three-dimensional structure of M. tuberculosis dihydrofolate

- reductase reveals opportunities for the design of novel tuberculosis drugs". *J. Mol. Biol.* 295 (2): 307–23. doi:10.1006/jmbi.1999.3328. PMID 10623528, (January 2000).
- 19. Benkovic SJ, Fierke CA, Naylor AM. "Insights into enzyme function from studies on mutants of dihydrofolate reductase". *Science* 239 (4844): 1105–10. doi:10.1126/science.3125607. PMID 3125607, (March 1988).
- 20. Hawser S, Lociuro S, Islam K. "Dihydrofolate reductase inhibitors as antibacterial agents". *Biochem. Pharmacol.* 71 (7): 941–8. doi:10.1016/j.bcp.2005.10.052. PMID 16359642, (March 2006).
- 21. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730961/
- 22. Khobragade C.N., Bodade R.G., Konda S.G., Dawane B.S., ManwarA.V., Synthesis and antimicrobial activity of novel pyrazolo[3,4-d]pyrimidine derivatives, *European Journal of Medicinal Chemistry*, 2010, 45, 1635–1638.
- 23. Minfo.cancerresearchuk.org/ cancerstats (WHO).
- 24. Mishra R., Tomar I, Review article, pyrimidine: the molecule of diverse biological and medicinal importance, *International Journal of Pharmaceutical Sciences and Research*, 2011, 2(4), 758-771.
- 25. Wilson C., Claudia R.B., Vellasco T, Chemistry and biological activities of 1,3- thiazolidin-4-ones, *Mini-Reviews in Organic Chemistry*, 2008, 5, 336-344.
- 26. Renslo A.R., Luehr G.W and GordeevM.F., Recent developments in the identification of novel oxazolidinone antibacterial agents, *Bioorganic and Medicinal Chemistry*, 14,4227–4240, 2006.
- 27. Ashok M., Holla B.S., Kumari N.S., Convenient one pot synthesis of some novel derivatives of thiazolo [2, 3-b] dihydropyrimidinone possessing 4-methylthiophenyl moiety and evaluation of their antibacterial and antifungal activities, *European Journal of Medicinal Chemistry*, 42, 380-385, 2007.
- 28. Zaher A., Elassar A.A., Bridgehead nitrogen thiazolopyrimidines, Sulfur Reports., 23(1), 47-77, 2002.
- 29. Akabari J.D., Kachhadia P.K., Tala S.D., Bapodra A.H., Dhaduk M.F., Joshi H.S., Mehta K.B. and Pathak S.J., Synthesis of some new 1, 2, 3, 4-tetrahydropyrimidine-2- t hiones and their thiazolo (3,2-a) pyrimidine derivatives as potential biological agents, *Phosphorus*, *Sulfur*, and *Silicon*, 2008, 1911-1922.
- 30. Kappe C.O., Review biologically active dihydropyrimidones of the biginelli-type a literature survey, European Journal of Medicinal Chemistry, 2000,35, 1043–1052.
- 31. Reddy C.S., Babu Y.H., Kumar M.A., Srinivasulu K., and Raju C.N., Synthesis and antimicrobial activity of novel 2- (heteryl- carboxamido)-2,3-dihydro-1*H*-1,2,5- oxadiazolo [3,4-*c*] [1,3,2] diazaphosphole-2-oxides, *ARKIVOC*, 2006, (xv), 189-197.
- 32. Salahuddin M.D., Kakad S. and Shantakumar S.M., Synthesis of some novel thieno [2, 3-d] pyrimidines and their antibacterial activity, *European Journal of Chemistry*, 6(3), 801-808, 2009.
- 33. Omar M.A., Galil A.E., Synthesis of some new pyridine-6-carboxamide derived schiff bases as potential antimicrobial agents, *Molecules*, 15(7), 4711-4721, 2010.
- 34. Arayne M.S., Sultana N., Haroon U., Zuberi M.H., Bushra S., Rizvi S., Synthesis, characterization and biological activity of series of carboxamide derivatives of ofloxacin, *Archives of Pharmal Research*, 2010, 33(12), 1901-1909.

- 35. Matthews DA, Alden RA, Bolin JT, Freer ST, Hamlin R, Xuong N, Kraut J, Poe M, Williams M, Hoogsteen K "Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate". *Science* 197 (4302): 452–455. doi:10.1126/science.17920. PMID 17920., (July 1977).
- 36. Filman DJ, Bolin JT, Matthews DA, Kraut J. "Crystal structure of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis". *The Journal of Biological Chemistry* 257 (22): 13650–13662. PMID 6815179., (November 1982).
- 37. Osborne MJ, Schnell J, Benkovic SJ, Dyson HJ, Wright PE "Backbone dynamics in dihydrofolate reductase complexes: role of loop flexibility in the catalytic mechanism". *Biochemistry* 40 (33): 9846–59. doi:10.1021/bi010621k. PMID 11502178., (August 2001).
- 38. Bolin JT, Filman DJ, Matthews DA, Hamlin RC, Kraut J. "Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate". *J. Biol. Chem.* 257 (22): 13650–62. PMID 6815178., (November 1982).
- 39. "Entrez Gene: DHFR dihydrofolate reductase".
- 40. Schnell JR, Dyson HJ, Wright PE. "Structure, dynamics, and catalytic function of dihydrofolate reductase.".

 Annual Review of Biophysics and Biomolecular Structure 33 (1): 119–40. doi:10.1146/annurev.biophys.33.110502.133613. PMID 15139807., (June 2004).
- 41. Urlaub G, Chasin LA. "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity".

 Proc. Natl. Acad. Sci. U.S.A. 77 (7): 4216–20. doi:10.1073/pnas.77.7.4216. PMC 349802. PMID 6933469., (July 1980).
- 42. George M. and Joseph L., Textbook of pharmaceutical chemistry, First edition, Pulished by vinod vasishtha for viva books Pvt Ltd, 62-63, 2009.
- 43. Hill M. D., Movassaghi M., New Strategies for the Synthesis of Pyrimidine Derivatives: *Chem. Eur. J.*, *14*, 6836–6844. DOI: 10.1002/chin.2008.
- 44. Deshmukh M. B., Anbhule P. V., Jadhav S. D., Jagtap S. S., A novel and environmental friendly, one-step synthesis of 2,6-diamino-4-phenyl pyrimidine-5-carbonitrile using potassium carbonate in water: *Indian J. Chem.*, 47B, 792-795, 2008.
- 45. George M., Joseph L., "Textbook of Pharmaceutical Chemistry", Viva Books, 62-64, 2009.
- 46. Block J. H., Beale J. M., Organic medicinal and pharmaceutical chemistry, Eleventh edition, published by Lippincott William and Wilkins, 2004, 627-628.
- 47. Silverman R.B., "The Organic Chemistry of Drug Design and Drug Action", Second Edition, Academic Press, An imprint of Elsevier, 1, 2008.
- 48. http://www.wikipedia.com
- 49. Ashok M., Holla B.S., Kumari N.S., Convenient one pot synthesis of some novel derivatives of thiazolo [2, 3-*b*] dihydropyrimidinone possessing 4-methylthiophenyl moiety and evaluation of their antibacterial and antifungal activities, *European Journal of Medicinal Chemistry*, 42, 380-385, 2007 50. DOI: 10.1016/j.ejmech.2006.09.003.
- 51. Akabari J.D., Kachhadia P.K., Tala S.D., Bapodra A.H., Dhaduk M.F., Joshi H.S., Mehta K.B. and Pathak S.J.,

- Synthesis of some new 1, 2, 3, 4-tetrahydropyrimidine-2- thiones and their thiazolo (3,2-a) pyrimidine derivatives as potential biological agents, *Phosphorus*, *Sulfur*, *and Silicon*, 183, 1911-1922, 2008. 52. DOI: 10.1080/10426500701796330.
- 53. Muthumani P., Manojith, Meera R, Venkataraman S., Chidambaranathan N., Devi P., Sureshkumar C.A., Synthesis and biological evaluation of some novel pyrimidine derivatives, *International Journal of Pharmaceutical Sciences*, 3(1), 924-932, 2011.
- 54. Hawas U.W., Al-Omar M.A., Amr A.G.E., Hammam G., Synthesis of some thiopyrimidine and thiazolopyrimidines starting from 2,6-dibenzylidene-3- methylcyclohexanone, *Arabian Journal of Chemistry*,1-4, 2010.
- 55. Mulwad V.V., Parmar H.T., and Mir A.A., Synthesis of 7-methyl-3-(2-oxo-2*H* benzopyran-6-yl)-5*H*-1,4-thiazolo-[3,2-a]pyrimidin-5-one and its derivatives, *Journal of the Korean Chemical Society*, 54(1), 9-12, 2010.
- 56. Galil A.E., Amr E., Syntheis and antimicrobial activities of some thiopyrimidine and thiazolopyrimidine derivatives from 1-(2-chloro-6-ethoxy-pyridin-4-yl)-3-(4- fluorophenyl) prop-2-en-1-one, World Journal of chemistry, 4(2), 201-206, 2009/
- 57. Khobragade C.N., Bodade R.G., Konda S.G., Dawane B.S., Manwar A.V., Synthesis and antimicrobial activity of novel pyrazolo [3,4-d] pyrimidine derivatives, *European Journal of Medicinal Chemistry*., 45, 1635–1638, 2010.
 - DOI:10.1016/j.ejmech.2009.12.040.
- 58. Solanki M.J., ChavdaM.M. and Upadhyay J., Synthesis and antimicrobial activity of novel pyrazolo [3,4-d] pyrimidine derivatives, *International Journal of Chemical and Analytical Science*, 2(2), 15-17, 2011.
- 59. Joshi K. K., Synthesized the N-(4-chlorophenyl)-6-methyl-4-aryl-2-thioxo- 1, 2, 3, 4- tetrahydropyrimidine-5-carboxamide derivatives as antimicrobial activity: *Int. J. Chem.*, 56(7), 156-164, 2009.
- 60. Sawant R. L., Bhatia M. S., Synthesis, screening and QASR studies of 3-benzoyl-2- oxo-thioxo-1, 2, 3, 4-tetrahydropyrimidine analogues as antibacterial agents: *bull. Chem. Soc. Ethiop.* 22(3), 1-12, 2008,.
- 61. Fathalla O.A., Zeid I.F., Haiba M.E., Soliman A.M., Abd-Elmoez Sh. I., and El-Serwy W.S., Synthesis, antibacterial and anticancer evaluation of some pyrimidine derivatives: *World J. of Chem.*, 4(2), 127-132, 2009.
- 62. Ramesh B. And Kulakarni S.V. Design, synthesis and anticancer activity Of Some New Pyrimidine Derivatives: *Journal of Global Pharma Tech.* 2010, 2(4), 110-112, 2010.
- 63. Kumar B. R. P., Sankar G., Baig R. B. N., and Chandrashekaran S., Novel Biginelli dihydropyrimidines with potential anticancer activity: a parallel synthesis and COMSIA study: *Eur. J. med. Chem.*, 44, 4192-4198, 2009.
- 64. Abu-Hashem A.A., Youssef M.M. and Husseina A.R., Synthesis, antioxidant, antituomer activities of some new thiazolopyrimidines, pyrrolothiazolopyrimidines and triazolopyrrolothiazolopyrimidines derivatives, *Journal of the Chinese Chemical Society*, 58, 41-48, 2011.

- 65. Awadallah F.M., Synthesis, pharmacophore modeling, and biological evaluation of Novel 5*H*-thiazolo [3,2-*a*] pyrimidin-5-one derivatives as 5-HT_{2A} receptor antagonists, *Sci Pharm.*, 76, 415–438, 2008 66. DOI:10.3797/scipharm.0804-20.
- 67. Pathak A., Narayanaswamy V.K., Joshi A., RaoG.K. and Devi K., Synthesis of ethyl-5-(substituted phenyl)-7-methyl-3-oxo-3,5-dihydro-2H-thiazolo (3,2-a) -pyrimidine-6- carboxylates, *Indian Journal of Heterocyclic Chemistry*, 19, 273-276, 2010.
- 68. Khan S.A., Alam O., Siddiqui N., Ahsan W., Synthesis and pharmacological evaluation of newer thiazolo [3,2-a] pyrimidines for antiinflammatory and antinociceptive activity, *Medicinal Chemistry Research*, 19,1245–1258, 2010. 69. DOI: 10.1007/s00044-009-9267-8.
- 70. Muthumani P., Manojith, Meera R, Venkataraman S., Chidambaranathan N., Devi P., Sureshkumar C.A., Synthesis and biological evaluation of some novel pyrimidine derivatives, *International Journal of Pharmaceutical and Biological Archives*, 1(3),300-304, 2010.
- 71. Tozkoparan B., Ertan M., Kelicen P., Demirdamar R., Synthesis and antiinflammatory activities of some thiazolo [3,2-a] pyrimidine derivatives, *Il Farmaco*, 54,588–593, 1999
- 72. Sawant R. L., Sarode V. I., Synthesis, Spectral Characterization and Analgesic Activity of 2-Methylthio-1, 4-Dihydropyrimidines: *Iranian J. of Pharmaceutical research*, 10(4), 733-739, 2011.
- 73. Zhi H., Chen L., Zhang L., Liu S., Cheong Wan D.C., Lin H., Design, synthesis and biological evaluation of 5*H*-thiazolo [3,2*a*] pyrimidine derivatives as a new type of acetylcholinesterase inhibitors, *ARKIVOC*, xiii, 266-277, 2008.
- 74. Awadallah F.M., Synthesis, pharmacophore modeling, and biological evaluation of Novel 5*H*-thiazolo [3,2-*a*] pyrimidin-5-one derivatives as 5-HT_{2A} receptor antagonists, *Sci Pharm.*, 76, 415–438, 2008,. 75. DOI:10.3797/scipharm.0804-20.
- 76. Mohamed S.F., Flefel E.M., Galil A.E., Amr, Anti-HSV-1 activity and mechanism of action of some new synthesized substituted pyrimidine, thiopyrimidine and thiazolopyrimidine derivatives, *European Journal of Medicinal Chemistry*, 45, 1494–1501, 2010.
 - 77. DOI:10.1016/j.ejmech.2009.12.057.
- 78. Balkan A., S. U m a , Ertan M. and Wiegrebe W., Thiazolo[3,2-a]pyrimidinederivatives as calcium antagonists, *Pharmaize*, 47,687-688, 1992.
- 79. Molecular Design Suite 4.3, V Life Technologies, Pune, India
- 80. www.rcsb.com
- 81. Teodoro M. L., Phillips G. N., Kavraki L. E., Molecular docking: A problem with thousands of degree of freedom.
- 82. Kappe C.O., A reexamination of the mechanism of biginelli dihydropyrimidine synthesis. J. Org. Chem. 1997, 62,7201-7204.
- 83. De souza R.O.M.A., Penha E.T., Milarge H.M.S., The three component Biginelli reaction: A combined experimental and theoratical mechanistic investigation; Chem. Eur. J. 2009.

d360

- 84. Fathalla O.A., Zeid I.F., Haiba M.E., Synthesis, antibacterial and anticancer evalution of some anthracene derivatives; World journal of chemistry 4(2): 127-132,2009
- 85. Sawant R.L., Bhatia M.S., Synthesis, screening and QSAR study of 3-formyl-2-oxo- 1,2,3,4-tetrahydropyrimidine analogues as antibacterial agents; Int.J.Chem.Sci.:6(1), 45-58, 2008.
- 86. Mohammad A., Zahra Z., 1, 3-Dibromo-5, 5-dimethylhydantoin as a useful reagent for efficient synthesis of 3, 4-dihydropyrimidin-2-(1*H*)-ones under solvent-free conditions: *Chemical Papers.*, *63* (*1*), 97–101, 2009.
- 87. Fathalla O.A., Zeid I.F., Haiba M.E.; Synthesis, antibacterial and anticancer evalution of some Pyrimidine derivatives; World journal of chemistry 4(2): 127-132,2009
- 88. Gurdeep R. Chatwal., Shah K. Anand., Instrumental methods of chemical analysis, Himalaya Publishing House, 2.599-2.616.
- 89. Dr Kasture A.V., Dr Wadodkar S.G., Pharmaceutical analysis (Vol-II) Instrumental methods, Niraliprakashan, 267, 268, 281, 289, 308, 305, 306.
- 90. William kemp, Organic spectroscopy, Third edition, 52, 55, 56, 102, 286.
- 91. Robert M. Silverstein., Franciss X. Webster., Spectrometric identification of organiccompounds, Sixth Edition, 71-109.
- 92. Gready, J. E., Dihydrofolate reductase: binding of substrates and inhibitors and catalytic mechanism. Adv. Pharmacol. Chemother., 17, 37-102 (1980).
- 93. Blakley, R. L., Eukaryotic dihydrofolate reductase. Adv. Enzymol. Relat. Areas Mol.Biol., 70, 23-102(1995).
- 94. Costi, M. P., and Ferrari, S., Update on antifolate drugs targets. Curr. Drug Targets, 2,135-166 (2001).
- 95. Mathews, C. K., et al., Dihydrofolate reductase. Methods Enzymol., 6, 364-368 (1963).
- 96. Collins C.H., Lyne P.M., Grange J.M., Microbiological methods, Seventh Edition, K.M. Varghese Company, 178-205 (1995).
- 97. Presecott L.M., Harley J.P., Klein D.A., Microbiology, Sixth Edition, McGraw-Hillinternational edition, Singapore, 783,(2005).
- 98. Tortora, Funke, Case, Microbiology an introduction, Ninth edition, Pearson Education, 601-602, (2007).
- 99. Dr. Kokare C.R., Pharmaceutical microbiology experiment and techniques, SecondEdition. Career Publications, 138, (2007).
- 100. Dr. Gaud R.S., Dr. Gupta G.D., Practical microbiology, Fifth edition, Niraliprakashan, 40-41,(2006).
- 101. Sharma K., Manual of microbiology tools and techniques, Second edition, Anebooks Pvt. Ltd. New Delhi, 76-77, (2007).
- 102. James G.C., Natalie S., Microbiology: A laboratory manual, Sixth Edition, Pearson education, 135-289,(2005).
- 103. European Pharmacopeia, 2005, Vol-1, Council of Europe Strasbourg, Published by the directorate for the quality of medicines of the the council of Europe.
- 104. Indian Pharmacopoeia, 1996, Vol-2, Govt. of India, Ministry of Health and Family Welfare, Delhi, Publication by Controller of Publication.

d361

- 105. Vanicha Vichai, Kanyawim Kirtikara, Sulforhodamine B colorimetric assay forcytotoxicity screening, Nature Protocols, 1, 1112 – 1116, 2006.
- 106. NCI Protocols. In vitro methodology.

